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6 Zusammenfassung 
1. Zusammenfassung 
Die chronisch lymphatische Leukämie vom B-Zell Typ (B-CLL oder CLL) beschreibt eine maligne 
Transformation von reifen B-Lymphozyten und ist gekennzeichnet durch eine Anhäufung von CD19+ 
CD5+ monoklonalen B-Zellen. Zur Behandlung der CLL werden zurzeit Chemoimmunotherapie und die 
neuerdings zugelassenen Kinase-Inhibitoren verwendet. Trotz erheblicher Fortschritte auf dem Gebiet 
der CLL Therapie, bleibt die Krankheit, auch aufgrund vieler rezidivierender Krankheitsverläufe, 
unheilbar. Natürliche Killerzellen (NK Zellen) sind in CLL Patienten intrinsisch wirksam, können aber 
dennoch nicht zuverlässig gegen maligne B-Zellen rekrutiert werden. Lösliche Liganden für den 
aktivierenden NK-Zell Rezeptor NKG2D (Natural-killer group 2 member D) sind hauptsächlich an der 
Inhibition der NK-Zellaktivität in der CLL beteiligt. Aus diesem Grund sind neue Immunotherapien, die zu 
einer NK-Zell aktivierung gegen maligne Zellen führen von großer Bedeutung. 
Zu diesem Zweck habe ich rekombinante trispezifische Immunoliganden (Triplebodies) in drei 
verschiedenen Varianten entwickelt, die alle die NK-Zell Reaktivierung gegen CLL-Zellen zum Ziel haben. 
Unter autologen und allogenen Bedingungen haben wir erfolgreich den Triplebody ULBP2-aCD19-aCD19 
genutzt um NK-Zellen gegen die CD19+ CLL Zelllinie und gegen primäre Spendertumorzellen zu 
rekrutieren. Weiterhin haben wir die signifikante in vivo Wirksamkeit dieses Triplebodies im 
immunodefizienten Mausmodell (NSG mouse) nachgewiesen. Der Triplebodie ULBP2-aCD19-aCD33, der 
die Tumorzellen gleich an zwei verschiedenen Clustern bindet, wurde speziell entwickelt um auch bei 
Antigenverlust auf Tumorzellen im Krankheitsverlauf wirksam zu sein. Die duale Spezifität dieses 
Triplebodies führte zur Eliminierung von CD19+CD33+ Tumorzellen sowie CD19loss und CD33loss Varianten. 
Um die NK-Zell Aktivierung zu verstärken wurde die dritte Variante, ein dual-aktivierender Triplebody 
(ULBP2-aCD19-aNKR) entwickelt. Neben NKG2D stimuliert dieser Triplebody zusätzlich NKR (ein NK-Zell 
Rezeptor), einen weiteren wichtigen Rezeptor auf NK Zellen mit zytotoxischer Aktivität. Dies verstärkt 
die anti-Tumoraktivität gegen CLL Zellen erheblich. Die klinische Relevanz der drei Triplebody-Varianten 
wird im Kontext der CLL diskutiert. 
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2. Abstract  
Chronic lymphocytic leukemia of B cells (B-CLL or CLL) involves malignant transformation of mature B 
lymphocytes and is characterized by accumulation of CD19+ CD5+ monoclonal B cells. Chemo-
immunotherapy and recently approved kinase inhibitors are currently used for the treatment of CLL 
patients. Despite significant advances in the field, many patients relapse and CLL remains an incurable 
disease. Natural Killer (NK) cells in CLL patients are intrinsically potent but fail to be activated against 
malignant B cells. Soluble ligands for the Natural-killer group 2 member D (NKG2D), an activating 
receptor on NK cells, are one of the main players in inhibiting NK cell activity in CLL. To this end, novel 
immunotherapies that can harness NK cells to kill CLL cells are warranted.       
Here, I developed recombinant trispecific immunoligands (triplebodies) in three different formats but 
with a common aim to retarget NK cells against CLL. A mono-targeting triplebody ULBP2-aCD19-aCD19 
utilized an NKG2D ligand ULBP2 to successfully retarget NK cells against CD19+ CLL cell line and primary 
tumor cells in both, allogeneic and autologous settings. Further, significant in vivo potency of this 
triplebody was observed in immunodeficient (NSG) mouse model. A dual-targeting triplebody ULBP2-
aCD19-aCD33 was specifically generated to target antigen loss variants in cancer. Dual specificity of this 
triplebody was functional and could eliminate CD19+CD33+ tumor cells as well as CD19loss and CD33loss 
tumor variants.  
Finally, the third format – a dual activating triplebody ULBP2-aCD19-aNKR was developed to enhance 
the activation of NK cells. NKR is another major activating receptor on NK cells and stimulation of this 
receptor by the triplebody greatly improved the NK cell effector functions. Clinical implications and 
foreseeable challenges for all three triplebodies are discussed in the context of CLL. 
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3. Introduction 
3.1. Chronic lymphocytic leukemia (CLL)  
Chronic lymphocytic leukemia of B cells (B-CLL or CLL) is a disease involving malignant transformation of 
B lymphocytes and is the most commonly occurring leukemia in western countries, with more 
prevalence in males than in females (1.7 males for every female) [1, 2]. B lymphocytes originate from 
hematopoietic stem cells (HSCs) in the bone marrow where they also mature and constitute the 
humoral arm of the adaptive immune system [3]. Mature B cells express B cell receptor and migrate 
through secondary lymphoid organs such as lymph nodes and spleen where they can be activated upon 
antigen encounter to generate and secrete antibodies in normal conditions [4]. Typically, CLL affects 
mature B lymphocytes within peripheral blood, bone marrow, spleen or lymph nodes and can be 
characterized by progressive outgrowth and accumulation of CD19 and CD5 double positive monoclonal 
B cells [1, 4]. CLL is considered a disease of adults, mainly because the median age when CLL is 
diagnosed in the USA and Europe is 70 years with only 6% of total diagnosed cases below 50 years [1]. 
However, incidence of very early stage CLL with no clinical symptoms in younger patients is predicted to 
increase owing to increased awareness and frequent blood testing [5].    
In most cases, CLL patients do not show any apparent signs or symptoms and a routine blood test in 
most cases leads to the diagnosis [1, 6]. However, patients at very advanced stage can also be presented 
with enlarged lymph nodes (adenopathy), enlarged spleen (splenomegaly) and bone marrow infiltration 
[1]. Based on these aspects, two widely accepted staging systems were developed to classify patients 
within different stages of disease progression. While, the Rai system of staging CLL patients is more used 
in the USA, here in Europe, the Binet staging system is more preferred [7, 8]. As part of Binet staging, all 
patients (with adenopathy) are classified according to the areas of enlarged lymph nodes, anemia (low 
red blood cells) and thrombocytopenia (low platelets) [1, 8]. Binet A stage represents up to 2 enlarged 
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lymph node areas and no anemia and thrombocytopenia; Binet B stage represents 3 or more enlarged 
lymph node areas and no anemia and thrombocytopenia [1, 8]. Patients with anemia and/or 
thrombocytopenia irrespective of enlarged lymph nodes are classified into Binet C stage [1, 8]. These 
staging systems hold valuable prognostic information and are routinely used to decide the treatment 
options for patients [1, 6]. The University Hospital of Cologne is an active part of the German CLL study 
group (DCLLSG) and routinely treats many CLL patients according to the Binet staging, both, outside and 
within this study group. In this study, samples from several CLL patients that were staged by Binet 
system were collected and used for the experiments.  
3.1.1. Current therapeutic options for CLL  
Most CLL patients at Binet A and B stages and with inactive and asymptomatic disease do not undergo 
any treatment [6, 9]. Treatment is only initiated for patients at advanced (Binet C) stage or with active 
and symptomatic disease [6, 9]. In recent years, therapeutic options for CLL have advanced considerably 
with approval of two novel CD20 targeting humanized antibodies (obinutuzumab and ofatumumab) and 
kinase inhibitors such as ibrutinib and idelalisib [1]. Ibrutinib is a selective and irreversible inhibitor of 
Bruton’s tyrosine kinase (BTK) while idelalisib inhibits δ-isoform of phosphoinositide 3-kinase (PI3K) [10, 
11]. Patients with good physical condition receive a “gold standard” first-line chemo-immunotherapy 
regimen consisting a purine analogue fludarabine, cyclophosphamide and anti-CD20 chimeric antibody 
rituximab [1, 12]. 
In addition to the Binet staging, several genetic aberrations also provide prognostic and therapeutic 
indications [13, 14]. Loss of function of tumor suppressor TP53, by either deletion of the short arm of 
chromosome 17 (del(17p) or mutations in TP53 gene, is associated with resistance to genotoxic therapy 
that cannot be overcome by anti-CD20 antibodies [15, 16]. These patients are treated with novel kinase 
inhibitor, ibrutinib or idelalisib with or without rituximab [1]. Although, approval of these novel kinase 
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inhibitors has dramatically improved the care of unfit and poor risk (del(17p)) as well as relapsed CLL 
patients, many patients fail to respond and relapse following ibrutinib and idelalisib therapy. While, the 
mechanisms behind the resistance to idelalisib are not yet known, several acquired mutations have 
been recently identified in CLL patients that account for the resistance to BTK inhibitor ibrutinib [17-19].  
Alternatively, hematopoietic stem cell transplantation (HSCT) is the only known curative therapeutic 
option for CLL patients with sustained minimal residual disease (MRD) negativity in up to half of the 
HCST treated CLL patients [20]. Importantly, previously defined poor-risk factors such as del(17p) and 
resistance to chemo-immunotherapy do not affect the patients’ response to HSCT. Despite such 
favorable prospects, most CLL patients do not qualify for this option due to old age and lack of fitness, 
while some patients that undergo HSCT suffer from chronic graft versus host disease (GvHD) [20]. 
Therefore, novel therapies that are milder yet effective are warranted for such treatment refractory and 
other elderly and unfit patients. 
3.1.2. Promising immunotherapeutic approaches for CLL  
Over the last 30 years, researchers all over the globe have continuously explored the field of cancer 
immunotherapy, which is defined by the National Cancer Institute (NCI) as “..a type of biological therapy 
that uses substances to stimulate or suppress the immune system to help the body fight cancer”. Much 
of its success is attributed to therapies against hematological malignancies and for many cancers 
including CLL, some sort of immunotherapy is now being considered as a first-line therapeutic option 
[21]. For CLL, above mentioned FDA approved anti-CD20 antibodies (rituximab, obinutuzumab or 
ofatumumab), anti-CD52 antibody alemtuzumab and other promising anti-CD19 antibodies (MEDI-551 
and XmAb5574) that are currently in clinical trials are prime examples in this context. To this end, 
natural killer cells (NK cells) serve as an important effector population in CLL patients that mediate 
antibody-dependent cell mediated cytotoxicity (ADCC) response by these clinically successful antibodies 
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to kill cancer cells [22]. Moreover, much of the graft versus leukemia (GvL) effect of potentially curative 
allogeneic HSCT is also attributed to NK cell population within this graft making NK cell-based cancer 
immunotherapy as an attractive field of research [23, 24].  
3.2. Natural killer (NK) cells   
Natural killer (NK) cells were first identified in mice more than 30 years ago in 1975 by two independent 
researches named Rolf Kiessling and Ronald Herberman [25, 26], and later in the humans by Hugh Pross 
and Mikael Jondal [27]. These seminal studies identified NK cells as an immune cell population, which 
unlike T and B lymphocytes can mount a “natural” cytotoxic response against tumor cells from different 
donors (i.e. foreign or non-self) without pre-sensitization. Of note, my PhD work only involved working 
with human derived NK cells and hence, human NK cells are denoted simply as “NK cells” throughout 
this thesis. From more than three decades of intense work on NK cells, we now know that NK cells, along 
with B and T lymphocytes, are derived from the common lymphoid progenitor cells in the bone marrow. 
They are primarily found in bone marrow, peripheral blood and spleen but can also migrate to tonsils, 
thymus and uterus [24]. NK cells are classically defined as CD56 positive but do not express pan T-cell 
marker CD3. Further, CD56+/CD3- NK cells can be divided into two subpopulations depending upon the 
surface expression of CD56 [24]. While, the CD56low/CD16+ NK cell subset is primarily cytotoxic and 
accounts for 90% of NK cells found in peripheral blood, the CD56bright/CD16- subset is predominantly 
located within lymph nodes and exert immune regulatory functions by producing cytokines such as IFNγ 
and TNFα [24].  
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3.2.1. Activating and inhibitory receptors on NK cells  
NK cells express a diverse array of activating and inhibitory receptors and, as shown in the introduction 
figure 1 (taken from [28]), a dynamic balance between the signaling from these two sets of receptors 
determine the fate of NK cell activation [29].  
 
 
Introduction figure 1. Activation of NK cells is regulated by activating and inhibitory signals. (A) NK 
cells are tolerant towards healthy cells that express self MHC-I molecules and very low or no 
activating ligands. (B and C) Loss of expression of MHC-I molecules on virally infected or tumor cells 
(“Missing self”) or overexpression of activating ligands on stressed or tumor cells even in the 
presence of self MHC-I (“Induced self-ligands”) leads to the activation of NK cells. (D) NK cells can also 
be activated by stimulation of CD16 receptor by tumor-antigen specific antibodies in a process known 
as antibody-dependent cell mediated cytotoxicity (ADCC).        
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Killer-cell immunoglobulin-like receptors (KIRs) and CD94/NKG2A are inhibitory receptors on NK cells 
which upon binding to their respective ligands, HLA-A/B/C and HLA-E, send an inhibitory signal to NK 
cells via intracellular tyrosine-based inhibitory motif (ITIM) that results in NK cell tolerance to the “self-
normal” cells [24]. Viral infection or malignant transformation of cells downregulate the HLA molecules 
in order to escape T cell response, but in turn, alert the NK cells to mount a killing response (also known 
as “missing-self” hypothesis). Moreover, stressed or transformed cells can also upregulate certain stress-
induced proteins on the cell surface which serve as natural ligands for activating receptors on NK cells. In 
what is known as “induced-self” hypothesis, expression of ligands on target cells for NK-cell activating 
receptors can overcome the tolerance and activate NK cells despite the presence of same levels of self-
HLA molecules [24, 29].   
Several diverse activating receptors are expressed on NK cells. Some of the characterized activating 
receptors on NK cells include 2B4, DNAM-1 and NKG2C/CD94. One important set of receptors from the 
immunoglobulin superfamily are called natural cytotoxicity receptors (NCRs) and include NKp30, NKp44 
and NKp46 [24]. Cell surface expression of NKp44 can only be induced in response to NK cell activation 
[30], while expression of NKp46 is constitutive and restricted to NK cells, making it a valuable NK cell 
marker [31]. Recently, proliferating cell nuclear antigen (PCNA) and mixed lineage leukemia 5 (MLL5) 
have been identified as natural ligands for NKp44 [32, 33], and vimentin is identified as a ligand for 
NKp46 [34]. NKp30 is the most studied NCR in the context of cancer immunology. BCL2-associated 
athanogene 6 (BAG6/BAT3) and B7 family member B7-H6 are recently discovered natural ligands for 
NKp30. BAG6, when expressed on the surface of exosomes, can activate NK cells via NKp30 to induce 
target cell killing of tumor cells and immature DCs [35, 36]. Expression of B7-H6 is more tumor-specific 
and is found on the surface of cells or extracellular vesicles (exosomal fractions) [37, 38].  
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One of the most potent and clinically utilized activating receptor on NK cells is low affinity Fc receptor 
FcγRIIIa or CD16a, which induces strong antibody-dependent cell mediated cytotoxicity (ADCC) response 
upon binding to the Fc portion of IgG antibody (Introduction figure 1d). Most clinically used antibodies 
for CLL and many other malignancies take advantage of CD16a receptor on NK cells [39]. NKG2D is a 
homodimeric type II transmembrane protein belonging to the family of C-type lectin-like receptors. 
Various stress-induced proteins such as MICA, MICB and UL16-binding proteins (ULBP1-6) are natural 
ligands for NKG2D and expressed upon infection and malignant transformation [40].  
Introduction figure 2. Signaling components of major NK cell activating receptors. A homodimer of 
NKG2D receptor associates with two dimers of DAP10 adaptor molecules containing an YxxM motif. 
Upon ligand binding, DAP10 phosphorylates p85 subunit of the PI3K and Grb2. CD16a (FcγRIIIa) as 
well as natural cytotoxicity receptors (NCRs) including NKp30 and NKp46 associate with homodimers 
or heterodimers of CD3ζ and FcRγ chains while NKp44 associates with homodimers of DAP12 
adaptor molecules. All these adaptor molecules contain immunoreceptor tyrosine-based activation 
motif (ITAM) that activates downstream pathway via SyK and ZAP70 upon respective ligand binding. 
Intracellular domain of 2B4 receptor contains immunoreceptor tyrosine-based switch motif, which - 
upon ligand (CD48) binding - activates adaptor molecules SAP, Fyn and subsequently downstream 
signaling molecules Vav1 and PLCγ1.      
NKp46 and NKp30 associate with disulfide-linked homodimers or heterodimers of the TCR ζ and/or 
the FcR γ chains, whereas NKp44 associates with he disulfide-li ked homodimer DAP12. All th se 
signaling partners contain an immunoreceptor-based activation motif (ITAM) in their cytoplasmic 
tail. NCR engagement induces Src-family kinase-mediated tyrosine phosphorylation of the ITAM 
sequence in the associated partner chains. This induces binding of tyrosine kinases Syk and ZAP70 to 
the ITAM.  
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As shown in the introduction figure 2, these diverse activating receptors on NK cells associate with 
distinct adaptor molecules to signal for NK cell induced killing of target cells via perforin and granzyme 
dependent apoptosis. Of note, NK cells can also induce the extrinsic apoptosis pathway in target cells via 
death ligands namely tumor necrosis factors alpha (TNFα), TNF-related apoptosis-inducing ligand (TRAIL) 
or CD95L (Fas ligand) [24]. 
3.3. NK cell mediated surveillance in CLL patients is defective  
NK cells are equipped with multiple attack mechanisms and should eliminate any malignant B cells 
before they progress to CLL. However, CLL cells do escape NK cells and possibly other potent immune 
cells by mechanisms which are not yet completely understood [41]. There have been many studies to 
analyze the possible defects in the cross-talk between malignant B cells and NK cells in CLL patients and 
all studies could confirm the inability of NK cells to kill CLL cells from the same patients in an autologous 
setting (introduction figure 3; adapted from [41]).  
The expression level of NKG2D, CD16, NKp46, DNAM-1 and 2B4 on NK cells were unaltered between CLL 
patients and healthy age-matched controls. However, the expression of NKp30 was found to be slightly 
but significantly downregulated on NK cells from CLL patients [42, 43]. Many ligands for activating and 
inhibitory receptors were also assessed on CLL cells which appeared to be the more probable reason for 
NK cell resistance. Veuillen et al showed that CLL cells downregulated the surface expression of NKG2D 
ligands ULBP1, ULBP2, MICA and MICB in order to escape NK cell response, while HLA-E, a ligand for an 
inhibitory receptor CD94/NKG2A, was overexpressed [44]. Previously, our lab has shown that the high 
levels of soluble ligands MICA/B, ULBP2 (NKG2D ligands) and BAG6 (NKp30 ligand) as well as other 
soluble factors in CLL plasma hampered the NK cell cytotoxicity [43]. BAG6 is an NKp30 ligand which 
activates NKp30 receptor when expressed on the exosomes but inhibits it in soluble form [35]. 
Additionally, soluble NKG2D ligands in CLL can also be used as prognostic markers [45]. In tumor cells, 
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matrix metalloproteinases can shed the ligands from the surface of cell or exosomal membrane and 
thereby evade immune stimulation [46]. In addition to these functional changes in both NK and CLL cell 
compartments, few studies have identified the low number of NK cells in CLL patients as a main reason 
for defective NK surveillance [47, 48].    
 
3.4. NK cells can be retargeted against CLL cells  
Researchers have worked on different therapeutic strategies to empower NK cells against malignancies 
including CLL. Checkpoint blockade is one such strategy that involves blocking of the inhibitory receptors 
on immune cells to reverse the immune suppression by tumor cells. Recent success in blocking of 
inhibitory receptors on T cells such as CTLA-4 and PD-1 by FDA approved antibodies (checkpoint 
Introduction figure 3. Factors contributing in NK cell evasion of CLL cells. Overexpression of 
inhibitory ligands (HLA-E) and/or downregulation or proteolytic shedding (by MMPs) of activating 
ligands (for NKG2D and NKp30 receptors) on CLL cells allow NK cell escape. Soluble factors such IL10, 
TGFβ and ligands for activating NK cell receptors can inhibit NK cells, possibly by downregulating the 
correspondent receptors on the surface of NK cells. 
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inhibitors) has led to the development of novel checkpoint inhibitors for NK cells [49, 50]. Two promising 
antibodies blocking NK cell inhibitory receptors KIR (Lirilumab, Innate Pharma) and CD94/NKG2A 
(IPH2201, Innate Pharma) are currently in clinical trials (NCT01714739 and NCT02331875, respectively) 
[51]. Alternatively, a few studies particularly focused on expanding NK cell population to increase the 
above mentioned low NK:CLL ratio in CLL patients [47, 52]. To this end, advances in the field of adoptive 
NK cell transfer have been reviewed and suggested the use of NK cells from different sources such as 
haploidentical donors and NK cell lines (e.g. NK-92) [53, 54].  
We and others have utilized recombinant DNA technology to generate mAb-based bispecific and 
trispecific constructs in different formats to activate NK cells. I have reviewed the progress in the field of 
constructs activating, both, T and NK cells against cancer and also suggested two terms to clearly 
distinguish different formats of such constructs [55]. The term ‘immunoligand’ is used for recombinant 
constructs, which utilize natural ligands for the activating immune receptors fused to tumor-specific 
single chain fragment variable (scFv) part. While “immunoconstruct” can be considered as recombinant 
constructs that utilize antibody-derived components to target both immune cells and target cells. 
Several bispecific and trispecific immunoconstructs have been studied, all with an anti-CD16 scFv moiety 
to activate NK cells (via CD16a receptor), while, NK cells were specifically retargeted against various 
tumor entities by respective scFv moieties against tumor antigens such as CD30, CD33, CD123, and CD19 
[56-61].  
We particularly focused on developing recombinant immunoligands containing human NKG2D ligand 
ULBP2 fused to tumor antigen specific scFv. The idea is that these immunoligands will bind specifically to 
the tumor antigens and will coat the tumor cells with ULBP2 ligand. This will turn the otherwise NK cell 
resistant tumor cells visible to NK cells for attack. The first immunoligand ULBP2-BB4 retargeted NK cells 
(by ULBP2) against CD138+ multiple myeloma cells (by BB4 scFv) (cell lines and primary patient tumor 
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cells) and also showed significant antitumor activity in a xenograft mouse model [62]. Subsequently, two 
additional immunoligands in similar formats but targeting different tumor antigens [CEA and prostate-
specific membrane antigen (PSMA)] also validated our approach [63, 64]. CEA and PSMA are tumor-
specific antigens with frequent overexpression on colon and prostate cancers, respectively. Recently, 
other groups also developed NKG2D targeting immunoligands, albeit using an alternative NKG2D ligand 
MICA. This CD20 (7D8 scFv) specific immunoligand MICA-7D8 could also retarget NK cells against CD20+ 
lymphoma cells thereby validating this approach [65].   
As reviewed above, CLL cells frequently downregulate or shed ligands for activating NK receptors 
including NKG2D as a mean to evade NK cell response. Therefore, our immunoligand-based strategy to 
coat CLL cells with ULBP2, a natural ligand for NKG2D, should re-sensitize them for NK cell mediated 
immune response. To this end, following the encouraging results with bispecific immunoligands, one 
aim of this thesis was to generate the trispecific immunoligand containing ULBP2 to activate and 
retarget NK cells against CLL cells.       
3.5. Mono-targeting trispecific immunoligand (triplebody) - ULBP2-aCD19-aCD19  
The term “mono-targeting triplebody” represents a trispecific immunoligand but targeting a single 
antigen on cancer cells.  ULBP2-aCD19-aCD19 contained ULBP2 and two CD19 specific scFvs in a single 
polypeptide chain separated by a glycine-serine linker to confer the flexibility to each arm. 
CD19, a transmembrane glycoprotein, is expressed on various B cell malignancies corresponding to 
different stages of B cell maturation including CLL. Expression of CD19 is found to be very low on healthy 
B cells while is undetectable on hematopoietic stem cells making it an attractive target for 
immunotherapy [55]. CD19 antigen is clinically validated by a FDA approved bispecific T cell engager 
(BiTE®) Blinatumomab [66] as well as by promising anti-CD19 antibodies and CD19 specific CAR-T cell 
therapy against CLL [1, 55]. 
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As shown in the introduction figure 4, it is expected that ULBP2-aCD19-aCD19 will bind specifically to 
CD19 antigens on CLL cells allowing free ULBP2 ligand on the surface of CLL cells to interact with the 
NKG2D receptor on NK cells, thereby, bringing NK cells in the close proximity of CLL cells. This way NK 
cells can be activated to specifically kill CLL cells and to secrete cytokines such as IFNγ and TNFα.      
3.6. Antigen loss variants in leukemia result in therapy resistance and tumor relapse  
Cancer, though originating from a single cell, consists of a pool of heterogeneous cell clones with diverse 
genetic and phenotypic makeup. During the course of progression, tumor cell clones negative for the 
expression of a particular tumor antigen can be naturally selected and may outgrow the clones that 
express that antigen or the heterogeneous clones can simply coexist [67]. In such cases, targeted 
Introduction figure 4. Rational for a mono-targeting triplebody - ULBP2-aCD19-aCD19. ULBP2-
aCD19-aCD19 can bind to CD19 on CLL cells with higher avidity due to two CD19 specific scFvs, 
thereby retargeting NK cells against CLL cells via NKG2D receptor. 
NKR 
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immunotherapies specific for a single tumor antigen, including mAb or immunoligand-based therapies, 
can be partially successful but may give rise to antigen negative tumor relapse.  
Additionally, there are reports suggesting the direct role of targeted therapies in antigen loss on tumor 
cells. CLL and mixed lineage leukemia (MLL) both have been studied in this regard. Mostly, mAb 
therapies against CLL have caused surface antigens to be lost from the cell surface [68-71]. Mixed 
lineage leukemia (MLL) is childhood leukemia with a very poor prognosis due to rearrangements of the 
mixed lineage leukemia (MLL) gene on chromosome 11q23 and characteristically expresses a typical 
lymphoid marker CD19 and a myeloid marker CD33 [72]. Recently, few cases of B cell acute lymphoid 
leukemia (B-ALL) with MLL rearrangements were reported, where CD19 directed CAR T cell therapy 
resulted in the relapse of clonally related acute myeloid leukemia with typical myeloid expression 
patterns, a phenomenon termed as a lineage switch [72].  
Taken together, tumor relapses involving antigen loss variants are often more aggressive and difficult to 
manage which needs to be addressed in designing novel immunotherapies to move ahead in the 
direction of complete cancer cure. Thus, taking advantage of the triplebody format, dual-targeting 
trispecific immunoligands (triplebodies) were designed in this project. 
3.7. Dual-targeting trispecific immunoligand (triplebody) – ULBP2-aCD19-aCD33 
The term “dual-targeting triplebody” represents a trispecific immunoligand targeting two distinct 
antigens on cancer cells.  ULBP2-aCD19-aCD33 contained ULBP2 as a natural ligand and a CD19 specific 
and a CD33 specific scFv in a single polypeptide chain separated by a glycine-serine linker to confer the 
flexibility to each arm. The lymphoid antigen CD19 was already introduced above (in chapter 3.5) and 
the sialic acid binding transmembrane receptor CD33, which is typically expressed by myeloid cells, is 
also a clinically validated antigen [73].  
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In this thesis, ULBP2-aCD19-aCD33 was developed to assess whether dual specificities can eliminate 
antigen loss variants where a mono-targeting approach would fail (introduction figure 5). Mixed lineage 
leukemia (MLL) with dual expression of CD19 and CD33 was used as a model in this regard, but this 
approach is applicable to any other cancer type including equally relevant CLL.  
 
 
 
 
 
Introduction figure 5. Rational for a dual-targeting triplebody - ULBP2-aCD19-aCD33. ULBP2-aCD19-
aCD33 can retain specificity not only for double antigen positive target cells (CD19+CD33+ MLL) but 
also for antigen loss variants that have lost the expression of either of CD19 and CD33 antigens. Of 
note, although shown for mixed lineage leukemia (MLL) as an example, this rational is equally 
relevant for other cancers such as CLL.    
NKR 
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3.8. Synergy among multiple activating receptors on NK cells for enhanced effector 
functions  
As already shown before, NK cells can be retargeted by multiple activating receptors, many of which 
utilize distinct adaptor molecules and signaling components to activate NK cells. To assess an individual 
role of a single activating receptor on NK cell in response to target cells is not straightforward, as typical 
target cells such as tumor cells often express several known and unknown NK cell ligands. To address 
these specific questions, Eric Long’s group developed a Drosophila expression system with regulated 
expression of a single or a combination of NK cell ligands without the interference of any other known or 
unknown NK cell ligands [74]. Drosophila Schneider-2 (S2) cell line, derived from a late stage embryo of 
Drosophila melanogaster, do not express any ligands for human NK cells and are easy to transfect and 
culture and therefore, served as a useful system to study NK cell activation [74, 75].  
Synergy among activating receptors such as NKG2D, LFA-1, CD16 and 2B4 was explored in resting NK 
cells using transfected Schneider-2 cells expressing respective human NK ligands. Interestingly, this 
approach revealed that receptors can signal independently in resting NK cells but this is in most cases 
not sufficient to trigger all functional aspects such as adhesion, granule polarization and degranulation, 
which are all essential for cytotoxicity [76, 77]. For example, LFA-1 engagement triggers adhesion and 
granule polarization while CD16 activation signals for degranulation – only synergistic activation of both 
can mediate cytotoxicity by resting NK cells [78]. Similarly, synergistic activation of NKG2D and 2B4 
receptors can induce resting NK cells to kill the target cells while individual stimulation of NKG2D or 2B4 
is not sufficient [76]. 
Schneider-2 cells were also used in this thesis to address the role of cytokine priming on NKG2D 
stimulation alone or in combination with CD16a stimulation on NK cells.  
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3.9. Dual-activating trispecific immunoligand (triplebody) – ULBP2-aCD19-aNKR 
The term “dual-activating triplebody” represents a trispecific immunoligand with two arms activating 
distinct receptors on NK cells and one scFv against a single tumor antigen. ULBP2-aCD19-aNKR 
contained a CD19 specific scFv moiety flanked by ULBP2, a natural ligand for NKG2D, and NKR activating 
scFv, all in a single polypeptide chain separated by a glycine-serine linker to confer the flexibility to each 
arm (introduction figure 6).  
 
 
 
 
 
 
 
 
 
 
 
Introduction figure 6. Rational for a dual-activating triplebody - ULBP2-aCD19-aNKR. ULBP2-aCD19-
aNKR, a CD19 specific triplebody developed for CLL, can simultaneously stimulate both, NKG2D and 
NKR receptors on NK cells. This can result in enhanced activation and more potent retargeting of NK 
cells against CLL cells.  
NKR 
aNKR 
ULBP2-aCD19-aNKR 
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3.10. Specific aims of this thesis  
Taken together, CLL is a relevant disease for the development of novel NK cell based immunotherapies. 
Our idea is to coat (opsonize) CLL cells with NK cell activating ligands in the form of different triplebodies 
to re-sensitize them for NK cell surveillance. Antigen loss from tumor cells, via natural or therapy 
induced mechanisms, is particularly addressed in this regard. Triplebodies in three different formats will 
be studied in this thesis to address the following topics.  
i. To assess whether priming of NK cells with different cytokines (IL2, IL12, IL15, IL18) can 
modulate NKG2D receptor induced NK cell effector functions. To this end, Schneider-2 cells 
expressing ULBP1 (NKG2D ligand) are used. 
 
ii. To develop a mono-targeting triplebody ULBP2-aCD19-aCD19 to retarget NK cells via NKG2D 
receptor against CLL cell line and primary CLL cells. Particularly, to assess the ability of ULBP2-
aCD19-aCD19 to overcome NK cell inhibitory factors in CLL patients’ serum. To test the tumor 
limiting effects of ULBP2-aCD19-aCD19 in an immunodeficient xenograft mouse model. 
 
iii. To develop a dual-targeting triplebody ULBP2-aCD19-aCD33 with a view to retarget NK cells 
against antigen loss variants in cancer. To use CD19+CD33+ MLL cells as targets in order to test 
the proof-of-principle that can also be applied to other cancers such as CLL. 
 
iv. ULBP2-aCD19-aNKR was developed to assess whether activation of NKR in addition to NKG2D 
receptor on NK cell confers any advantage in terms of NK cell cytotoxicity and cytokine 
secretion in response to CLL cells                
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4. Materials and Methods 
4.1. Cell culture 
4.1.1. Drosophila Schneider 2 (S2) cells  
The Schneider 2 (S2) cell line was derived from a late stage embryo (20-24 days old) of Drosophila 
melanogaster and shares many characteristics from a macrophage-like lineage [75]. A frozen aliquot of 
Schneider 2 cells was provided in DES®-Blasticidin support kit (Cat. Nr. K515001, ThermoFisher 
Scientific). Schneider 2 cells were cultured in Schneider’s Drosophila medium (Cat. Nr. 21720-024, 
ThermoFisher Scientific) supplemented with 10% fetal bovine serum (Invitrogen). Schneider 2 cells were 
grown at 27°C without CO2 as a suspension cell line and cells were passaged every 2-3 days. Cells were 
regularly checked for mycoplasma contamination by polymerase chain reaction (PCR) and only cell lines 
negative for mycoplasma contamination were used for experiments. 
4.1.2. Human derived cell lines and primary CLL cells 
Human embryonic kidney-derived cell line 293T (HEK293T), chinese hamster ovary cell line CHO, chronic 
B cell leukemia cell line MEC1, pro-B ALL-derived cell line SEM, pre-B phenotypic cell line BV173 and 
acute myeloid leukemia cell line HL60 were purchased from DSMZ. HEK293T and CHO were cultivated in 
Dulbecco’s MEM medium (Invitrogen), SEM was cultivated in Iscove’s MDM (Cat. Nr. 12440053, 
Invitrogen) while MEC1, HL60 and BV173 were cultivated in RPMI-1640 medium (Cat. Nr. 61870010, 
Invitrogen). All cells were cultivated at 37°C and in 5% CO2 atmosphere. Mediums for the cell lines were 
supplemented with 10% (vol/vol) heat-inactivated fetal calf serum (Invitrogen) and 50 µg/mL penicillin, 
50 µg/mL streptomycin and 2 mM L-glutamine. 
Peripheral blood from chronic lymphocytic leukemia patients (CLL) was collected by CLL biobank, 
University Hospital Cologne and B cells were purified on the same day. Freshly purified CLL were 
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Cell line Origin 
Drosophila Schneider-2 
Late stage (20–24 hours old) Drosophila Melanogaster 
embryos  
HEK293T Human embryonic kidney  
CHO Ovary of the Chinese hamster 
MEC1 Peripheral blood of a chronic B-cell leukemia (B-CLL) patient  
HL60 Acute promyelocytic leukemia patient   
BV173 B cell precursor leukemia cells from the peripheral blood of 
a patient with chronic myeloid leukemia (CML) in blast crisis 
SEM B cell precursor leukemia cells from the peripheral blood of 
a patient at relapse of acute lymphoblastic leukemia (ALL)  
 
Table: Cell lines 
received from the CLL biobank and were cultured overnight in Panserin 411S (Cat. Nr. P04-7411S1, Pan-
Biotech, Germany). Sampling of blood samples (CLL patients and healthy donors for NK cell purification 
(next)) was approved by the local ethics committee of the University of Cologne under reference 
numbers 11-140 and 08-275, and donors provided written consent in accordance with the Declaration of 
Helsinki. 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.3. Primary natural killer (NK) cells: Purification and culturing 
Buffy coats from healthy donors were provided by the blood bank of University Hospital Cologne. Blood 
sampling was approved by the local ethics committee of the University of Cologne under reference 
numbers 11-140 and 08-275. Peripheral blood mononuclear cells (PBMCs) were isolated from the buffy 
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coats by Ficoll-Paques density gradient centrifugation. These PBMC preparations were used to purify NK 
cells by negative selection using NK cell isolation kit (Miltenyi) and auto-MACS Pro Separator (Miltenyi, 
Bergisch-Gladbach, Germany) according to manufacturer’s instructions. In brief, depending upon the 
desired number of NK cells, specific number of PBMC were stained with a cocktail of primary antibody 
(specific for all immune cells but NK cells in PBMC) and magnetic beads coupled secondary antibody. The 
preparation was washed and run through the magnetic column to isolate non-labeled NK cells from the 
antibody bound other immune cells (negative selection). Purified polyclonal NK cells were cultivated 
overnight at 37°C in 5% CO2 atmosphere in Iscove’s Modified Dulbecco’s Medium (IMDM) + GlutaMAX™  
(Invitrogen) supplemented with 10% (vol/vol) heat-inactivated fetal calf serum (Invitrogen) and 50 
µg/mL penicillin, 50 µg/mL streptomycin and recombinant cytokine(s). Purified NK cells were primed by 
different cytokines depending upon the specific requirement of an experiment. Resting NK cells were 
incubated with recombinant human IL2 (10 U/ml). Additionally, NK cells were also primed by individual 
or combinations of following cytokines (also indicated in the respective legends of the figures): 
recombinant human IL2 (200 U/ml); IL15 (10 ng/ml); IL12 (10 ng/ml); IL18 (100 ng/ml). 
4.2. Cloning of Drosophila and mammalian expression vectors 
4.2.1. Generation of pAc5.1/V5-His_ULBP1 and pAc5-STABLE1-neo_ULBP1-GFP for 
constitutive expression of ULBP1 in Drosophila Schneider 2 cells  
A Drosophila constitutive vector pAc5.1/V5-His_ULBP1 was a kind gift by Dr. Yenan Bryceson (Karolinska 
Institute, Sweden) after we bought an empty pAc5.1/V5-His vector from Invitrogen (Cat. Nr. V411020) as 
it was a part of license agreement. pAc5.1/V5-His is a 5.4 kb expression vector and contains the 
Drosophila actin 5C (Ac5) promoter that allows high level, constitutive expression of desired protein in 
Drosophila cells. pAc5.1/V5-His vector contains an ampicillin resistance gene for selection of 
transformants in E. coli. However, it does not contain other selectable markers for selection of stably 
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transfected Drosophila cells and hence, the selection vector (pCoHygro or pCoBlast) needs to be co-
transfected to achieve stable cell lines exhibiting constitutive expression of the protein of interest. 
Moreover, it also contains C-terminal V5 epitope (Gly-Lys-Pro-Ile-Pro-Asn-Pro-LeuLeu-Gly-Leu-Asp-Ser-
Thr) and polyhistidine (6xHis) tag for detection and purification of the expressed protein.   
Initial small amount of pAc5.1/V5-His_ULBP1 was used for transformation of competent recA, endA 
E.coli strain TOP10 (One Shot® TOP10 chemically competent E.coli; Cat. Nr. C404010; Invitrogen). 
Transformation was done by mixing 1 ng of plasmid DNA with 100 µl of competent TOP10 cells on ice for 
30 min followed by heat shock at 42°C for 90 sec and 2 min cooling on ice. Transformed bacteria were 
spread onto 2YT agar plates with 100 µg/ml ampicillin concentration. 2YT-medium was prepared by 
dissolving 16 g Bacto Tryptone, 10 g Bacto Yeast and 5 g Nacl in 1 liter of ddH2O. To prepare 2YT agar, 
15g agar was dissolved in 1 liter of 2YT-medium. The plates were incubated at 37°C and on next day one 
clone was picked from the plate and 2YT medium was inoculated. This maxiprep sample was incubated 
at 37°C in shaker incubator for overnight. Following day, plasmid DNA was isolated from the maxiprep 
sample as instructed in manufacturer’s protocol (NucleBond Xtra® Maxiprep Kit; Cat. Nr. 740414.50, 
MN). Plasmid DNA was eluted ddH2O and was stored at -20°C for further use. A selection vector 
pCoBlast (DES®-Blasticidin support kit (Cat. Nr. K515001, ThermoFisher Scientific)) is a 3.9 kb vector 
containing a Drosophila copia promoter for high-level, constitutive expression of the blasticidin 
resistance gene (bsd) and was generated in same way and was stored at -20°C for further use. 
Another variant of above described Drosophila constitutive expression vector is pAc5-STABLE1-neo 
which allows multicistronic expression of GFP and Neomycin resistance gene under Ac5 promoter. 
Moreover, it also allows N-terminal or C-terminal fusion of desired gene sequence to GFP to generate 
GFP-fused protein of interest. Plasmid pAc5-STABLE1-neo was a gift from Rosa Barrio & James 
Sutherland (Addgene plasmid # 32425). ULBP1 cDNA was PCR amplified from pAc5.1/V5-His_ULBP1 
 
29 Materials and Methods 
vector to replace the restriction enzyme sites and was later cloned into pAc5-STABLE1-neo vector at the 
N-terminal part of GFP sequence to generate pAc5-STABLE1-neo_ULBP1-GFP.  
 
4.2.2. Generation of expression vectors for expression and secretion of bispecific 
immunoligands and trispecific immunoligands (triplebodies) in HEK293T and 
CHO cells  
A total of three different formats of triplebody and their respective bispecific counterparts were 
generated in this project. A mono-targeting triplebody ULBP2-aCD19-aCD19 and its bispecific 
counterpart ULBP2-aCD19 was generated with view to enhance the avidity for the target cells. A dual-
targeting triplebody ULBP2-aCD19-aCD33 was generated to specifically target antigen loss variants 
where ULBP2-aCD19 and ULBP2-aCD33 served as its bispecific counterparts. A dual-activating triplebody 
ULBP2-aCD19-aNKR was generated to enhance the activation of NK cells. A blocking construct – aCD19 
single chain (scFv) lacked ULBP2 and was used to block CD19 antigen in some experiments. Cloning of a 
bispecific immunoligand ULBP2-BB4 has been described in detail previously and was used as a backbone 
Plasmid Protein Product Promoter Tags 
pAc5.1_ULBP1 ULBP1 Drosophila Ac5 - 
pAc5_STABLE1_ULBP1 ULBP1-GFP Drosophila Ac5 GFP 
pL(aCD19scFv) Anti CD19 scFv CMV 6xHis 
pL(aCD33scFv) Anti CD33 scFv CMV 6xHis 
pL(ULBP2-aCD19) ULBP2-aCD19 CMV 6xHis; c-Myc 
pL(ULBP2-aCD33) ULBP2-aCD33 CMV 6xHis; c-Myc 
pL(ULBP2-aCD19-aCD19) ULBP2-aCD19-aCD19 CMV 6xHis; c-Myc 
pL(ULBP2-aCD19-aCD33) ULBP2-aCD19-aCD33 CMV 6xHis; c-Myc 
pL(ULBP2-aCD19-aNKR) ULBP2-aCD19-aNKR CMV 6x His; c-Myc 
 
Table: Plasmids 
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for the following clonings [62]. Human CD19-specific scFv (derived from 4G7 hybridoma, mouse IgG1), 
Human CD33-specific scFv and Human NKR-specific scFv (derived from XYZ hybridoma, mouse IgG1) 
were kind gifts by Dr Georg Fey (University of Erlangen-Nuremberg, Erlangen, Germany). The sequence 
of CD19- and CD33-specific scFv was optimized for improved expression and secretion in eukaryotic 
system (OptimumGene™ algorithm, Genscript Ltd.). Optimized aCD19scFv and aCD33scFv were cut at 
SfiI and NotI restriction sites and were cloned into the eukaryotic expression vector pL (ULBP2-BB4) to 
generate pL (ULBP2-aCD19) and pL (ULBP2-aCD33), respectively. Expression vector pL (previously 
designated as pMS) was described previously. In brief, pL is a derivative of the pSecTag2 plasmid 
(Invitrogen) that contains the IVS/IRES-EGFP sequence of the pIRES-EGFP plasmid (Clontech). Cloning of 
control constructs pL (aCD19) and pL (aCD33) was accomplished by PCR amplifying each scFv, thereby 
adding NheI site followed by human Ig kappa (Igk) light-chain signal peptide in front of aCD19 and aCD33 
scFv sequence, respectively, and cloning of each resulting PCR product into an empty pL vector. Finally, 
to generate all three triplebodies, aCD19, aCD33 and aNKR scFvs were PCR amplified from their 
respective backbones to replace SfiI by NotI restriction site at the 5’ end to generate each scFv sequence 
flanked by NotI sites. Each PCR product (scFv sequence) was cloned into a linearized pL (ULBP2-aCD19) 
to generate pL (ULBP2-aCD19-aCD19), pL (ULBP2-aCD19-aCD33) and pL (ULBP2-aCD19-aNKR).  
4.3. Transfection of cloned constructs into Drosophila and mammalian cells    
4.3.1. Calcium phosphate-based transfection of Schneider-2 cells 
To generate stable Schneider-2 cell line expressing ULBP1, cells were co-transfected by an expression 
vector pAc5.1/V5-His_ULBP1 for constitutive expression of ULBP1 and a selection vector pCoBlast for 
selection of stably transfected cells in 19:1 ratio using calcium phosphate transfection kit (ThermoFisher 
Scientific) according to manufacturer’s protocol. In brief, 3x106 cells were seeded in a single well of a 6-
well plate in complete Schneider’s Drosophila medium and on following day a mixture of solution A (2M 
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CaCl2 + 19µg pAc5.1_ULBP1 + 1µg pCoBlast) and a solution B (2x Hepes Buffered Saline (HBS)) was 
added dropwise to the cells and cells were further cultured for 2 days before analyzing the transient 
expression of ULBP1 and starting the Blasticidin selection. For selection of ULBP1 positive stable clones, 
cells were cultured for 2-3 weeks in presence of 25 µg/ml Blasticidin and cell surface expression of 
ULBP1 was monitored by FACS. A stable ULBP1 expressing Schneider-2 cell line (S2-ULBP1) was 
generated when ≈100% population was found to be positive for cell surface expression of ULBP1. Once 
selected, S2-ULBP1 cell line was maintained in complete Schneider’s Drosophila medium with 25 µg/ml 
Blasticidin and surface expression of ULBP1 was regularly monitored before experiments to maximize 
reproducibility. 
4.3.2. Lipid-based transfection of mammalian cells 
For expression of cloned constructs, HEK293T cells were transfected using Lipofectamine 2000 
(Invitrogen) according to manufacturer’s instructions. In brief, 4 µg of plasmid DNA and 10 µl of 
Lipofectamine were mixed to allow DNA-lipid complex formation. Once, incubated together the mixture 
was used to transfect 1 x 106 HEK293T cells in a 6 well tissue-culture plate (pre-seeded on the previous 
day). Two days after transfection, cells were transferred to a 75 cm2 medium flask (T75, Sarstedt) and 
were grown in RPMI-1640 + GlutaMAX™ (Invitrogen) supplemented with 200 µg/ml Zeocin (Invitrogen) 
for selection of stable clones. Following 2–3 weeks of selection and cultivation, stably transfected 
polyclonal clones were visible under fluorescence microscope, as all cloned constructs were expressed 
simultaneously with enhanced green fluorescent protein (EGFP) encoded by a bicistronic mRNA. For 
more efficient productivity, transfected HEK293T cells were further cultivated in serum-free CD293 
medium (Invitrogen) and supernatant was collected every 2 to 3 days for up to one month. The 
constructs which contained ULBP2 at the N-terminal were secreted into the S/N due to the inherent 
leader sequence of ULBP2 protein while the secretion of the blocking constructs aCD19scFv and 
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aCD33scFv was facilitated by Igκ-leader sequence at the N-terminal. The purification of His-tagged 
recombinant constructs was achieved by immobilized metal affinity chromatography (IMAC) using Ni-
NTA Sepharose (Qiagen) according to manufacturer’s protocol and constructs were eluted in elution 
buffer containing 250 mM imidazole. Subsequently, eluted constructs were dialyzed in PBS buffer.    
4.4. Detection of expressed proteins in both expression systems 
4.4.1. Surface expression of ULBP1 on Schneider-2 cells  
Both, ULBP1-expressing and wild type Schneider-2 cells were washed and resuspended in FACS buffer 
(PBS containing  0.2 % BSA and 0.2 % NaN3) at 1x106 cells/ml. 1x105 cells were stained with either 
relevant isotype antibody or mouse anti-human ULBP1 antibody for 30 min on ice. After thoroughly 
washing the unbound antibody, specifically bound primary antibody was detected by secondary 
phycoerythrin (PE) labeled antibody on ice in the dark. For exclusion of dead cells, 7-AAD (BioLegend) 
was added prior to measurement and only negative cells were included in analysis. FACS was performed 
on Gallios (Beckman Coulter). 
4.4.2. Western blot  
Purified bispecific immunoligands and triplebodies were mixed with Laemmli sample buffer (250mM Tris 
pH 7, 10% SDS, 50% Glycerol, 100mM DTT, 0,01% Bromophenol blue) and cooked at 95°C for 5 min and 
were subsequently loaded onto 10% SDS-polyacrylamide gels. The samples were separated for 1:30 
hours at constant 150 V and were transferred to the nitrocellulose membrane for further 1:30 hours at 
constant 0.35 Amp. Blots were overnight blocked at 4°C by 5 % non-fat milk (in 1x PBST) and on next day 
were incubated with primary c-Myc tag specific antibody (in 5 % milk) and HRP-tagged secondary 
antibody for 1 hour each. Proteins were detected with ECL (Thermo Scientific) using the digital Intas 
ChemoCam Imager.    
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4.4.3. Specificity assessment of immunoligands: Flow cytometry and ELISA  
Specificity of immunoligands to the respective target antigens (CD19 and/or CD33) was assessed by 
flow-cytometry (FACS). To this end, MEC1 (CD19+), HL60 (CD19-), BV173 (CD19+CD33+) and SEM 
(CD19+CD33+) cell lines were mainly used for following experiments. For all FACS-based specificity 
experiments, 1 x 105 cells resuspended in FACS buffer (PBS containing 0.2 % BSA and 0.2 % NaN3) were 
used per tube. Cells were then incubated with 10 µg/ml of a bi- or tri-specific immunoligand for 30 min 
on ice. Depending upon the experiment, CD19 and/or CD33 antigens were blocked on the cell line by 
addition of 20 µg/ml blocking constructs (aCD19scFv or aCD33scFv, respectively) prior to the incubation 
with the respective immunoligand in order to confirm the specificity of the latter. After thorough 
washing, bound immunoligands were stained by either mouse antibody against c-Myc tag (present on 
immunoligands) or by recombinant human NKG2D-Fc receptor that could bind to free ULBP2 moiety of 
immunoligand. Staining by NKG2D-Fc receptor could further confirm the ability of immunoligands to 
bind tumor antigen and NKG2D receptor simultaneously. Finally, PE-labeled anti-mouse antibody or 
AF647-labeled anti-Fc antibody could detect the c-Myc specific mAb or NKG2D-Fc receptor, 
simultaneously. Further, a CD19+/CD33- cell line MEC1 was used to assess the simultaneous binding 
ability of a dual-targeting immunoligand ULBP2-aCD19-aCD33.  
Here, recombinant human receptors NKG2D-Fc and CD33-FLAG (or DDK) were used in the same tube to 
detect CD19 antigen bound immunoligand. AF647-labeled anti-Fc antibody and PE-labeled FLAG (DDK) 
specific antibody provided the signals. For exclusion of dead cells, 7-AAD (BioLegend) was added prior to 
measurement and only negative cells were included in analysis. FACS was performed on a FACSCalibur 
(Becton Dickinson) or Gallios (Beckman Coulter). 
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Further, binding of ULBP2-aCD19 and ULBP2-aCD19-aCD19 to NKG2D receptor was also checked by 
ELISA. Recombinant human NKG2D-Fc receptor was coated at 100ng per well of a 96-well flat-bottom 
MaxiSorp™ plate. 10 µg/ml of immunoligand was added to each well whereby pre-blocking of NKG2D 
receptor by anti-NKG2D antibody (clone 1D11) confirmed the specificity. Finally, HRP-conjugated anti c-
Myc antibody could detect the bound immunoligand when the 1-step™ Ultra TMB-ELISA substrate 
(ThermoFisher Scientific) was added. 
 
 
 
Antibody Antigen Isotype Label* Application 
Concentration  
Supplier (Clone) 
(Cat. Nr.) 
LEAF™ anti-
NKG2D 
Human 
NKG2D 
Mouse 
IgG1 
- NKG2D blocking 
20 µg/ml 
BioLegend (1D11) 
(320810) 
FITC-anti-
NKG2D 
Human 
NKG2D 
Mouse 
IgG1 
FITC FACS 
1:100 dilution 
BioLegend (1D11) 
(320810) 
FITC-anti-
CD69 
Human 
CD69 
Mouse 
IgG1 
FITC FACS; Activation assay 
1:50 dilution 
BioLegend (FN50) 
(310904) 
BV421-anti-
CD56 
Human 
CD56 
Mouse 
IgG1 
BV421 Functional assays 
1:100 dilution 
BioLegend (HCD56) 
(318328) 
AF647-anti-
NKp46 
Human 
NKp46 
Mouse 
IgG1 
AF647 FACS 
1:100 dilution 
BioLegend (9E2) 
(331910) 
PE-anti-
CD107a 
Human 
CD107a 
Mouse 
IgG1 
PE Degranulation assay  
1:100 dilution 
BioLegend (1D4B) 
(121612) 
AF647-anti- 
IFNγ 
Human 
IFNγ 
Mouse 
IgG1 
AF647 IFNγ assay 
1:100 dilution 
BioLegend (4S.B3) 
(502516) 
FITC-anti- 
TNFα 
Human 
TNFα 
Mouse 
IgG1 
FITC TNFα assay 
1:100 dilution 
BioLegend (Mab11) 
(502906) 
Anti-ULBP1 Human 
ULBP1 
Mouse 
IgG2a 
- FACS 
10 µg/ml 
Bamomab (AUMO2) 
(AUMO2-500) 
 
Table: Antibodies  
*FITC, Fluorescein isothiocyanate; PE, Phycoerythrin; BV421, Brilliant Violet™ 421; AF647, Alexa 
Fluor® 647; PB, Pacific Blue™ ; HRP, Horseradish peroxidase. 
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4.5. Flow cytometry based investigation of NK cell effector functions  
4.5.1. Analysis of NK cell effector functions in response to NKG2D and/or CD16 
stimulation by Schneider-2 cells  
Purified 2.5 x 104 (resting or cytokine primed) NK cells were incubated with 2.5 x 104 Schneider-2 cells in 
“U” bottom 96-well plate for 6 hours for activation and cytokine assays and for 6 hours for 
degranulation assay. Schneider-2 cells expressing ULBP1 or coated with rabbit polyclonal serum were 
Antibody Antigen Isotype Label* Application 
Concentration  
Supplier (Clone) 
(Cat. Nr.) 
Anti-c-Myc c-Myc 
tag 
Mouse 
IgG1 
- FACS (10 µg/ml) 
Western blot (1:5000) 
Prepared in house 
(800 µg/ml) 
HRP-anti-
cMyc 
c-Myc 
tag 
Mouse 
IgG1 
HRP ELISA 
1:5000 dilution 
Life Technologies  
(R951-25) 
AF647-anti-Fc Human 
IgG 
Mouse 
IgG2a 
AF647 FACS 
1:100 dilution 
BioLegend (HP6017) 
(409320) 
PE-anti-
DDK/FLAG 
FLAG/ 
DDK tag 
Rat 
IgG2a 
PE FACS 
1:100 dilution 
BioLegend (L5) 
(637310) 
PB-anti-CD3 Human 
CD3 
Mouse 
IgG1 
PB FACS 
1:100 dilution 
BioLegebd (HIT3a) 
(300330) 
AF647-anti-
CD20 
Human 
CD20 
Mouse 
IgG2b 
AF647 FACS 
1:100 dilution 
BioLegend (2H7) 
(302318) 
PB-anti-CD5 Human 
CD5 
Mouse 
IgG2a 
PB FACS 
1:100 dilution 
BioLegend (L17F12) 
(364024) 
Goat anti-
mouse Ab 
Mouse 
IgG 
Goat 
polyclon
al IgG 
PE 
 
FACS  
1:100 dilution  
 
BioLegend (Poly4053) 
(405307) 
Goat anti-
mouse Ab 
Mouse 
IgG 
Goat 
polyclon
al IgG 
HRP Western blot and ELISA 
1:10,000 dilution 
Cell Signalling  
(7076p2) 
Isotype 
control Ab 
-  FITC, 
PE, 
AF647 
FACS  
 
Table: Antibodies (cont.) 
*FITC, Fluorescein isothiocyanate; PE, Phycoerythrin; BV421, Brilliant Violet™ 421; AF647, Alexa 
Fluor® 647; PB, Pacific Blue™ ; HRP, Horseradish peroxidase. 
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used as target cells to activate NKG2D or CD16a receptor on NK cells, respectively. At the end of the 
respective incubations, samples were stained with BV421™–labeled anti-human CD56 antibody to 
discriminate CD56-positive NK cells from CD56-negative Schneier-2 cells. NK cell activation was assessed 
by an additional FITC-labeled antibody staining for NK cell activation marker CD69. NK cell degranulation 
was assessed by flow cytometric analysis of the cell surface expression of the lysosomal protein 
CD107a.The last 4 hours of degranulation assay was carried out in presence of 2 µM monensin 
(BioLegend) and PE-labeled anti-human CD107a mAb because CD107a that has been externalized by NK 
cells upon degranulation is rapidly reinternalized. Similarly, last 4 hours of cytokine assay was carried 
out in presence of Brefeldin A (BFA) at a final concentration of 5 µg/ml as Brefeldin A is a protein 
transport inhibitor that leads to accumulation of most cytokines at the Golgi Complex/Endoplasmic 
Reticulum. For intracellular staining of IFNγ and TNFα in NK cells, cells were fixed and permeabilized 
using Cytofix/Cytoperm™ kit (BD Bioscience) according to the protocol and were subsequently stained 
with Alexa Fluor® 647-labeled anti-IFNγ and FITC-labeled anti-TNFα antibodies.  
4.5.2. NK cell cytotoxicity and degranulation by immunoligands 
Flow cytometry based NK cell cytotoxicity assays involved MEC1, HL60, BV173, SEM and primary 
malignant B cells from CLL patients at different stages. These target cells were labeled with lipophilic 
membrane dye DiR (Invitrogen) according to manufacturer’s instructions. Purified NK cells primed with 
different cytokines (See figure legends for details) were co-incubated with labeled target cells in “U” 
bottom 96-well plates at indicated E:T ratios with or without indicated immunoligands for 3 hours. At 
the end of co-culture, cells were stained with 7-AAD (BioLegend) and measured by flow cytometry 
(Gallios, Beckman Coulter). Gating on 7-AAD-positive population within DiR-positive population 
indicated dead target cells in percentage (%).Further, allogeneic toxicity assays with primary CLL cells 
were also done as above mentioned but in presence of 20% serum from CLL patients with known levels 
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of soluble NKG2D ligands. This was done to assess whether immunoligands can overcome the NK cell 
inhibitory effects of CLL serum in vitro. 
Toxicity assays involving mono-targeting triplebody (ULBP2-aCD19-aCD19) against MEC1 and HL60 cell 
lines as well as primary CLL cells utilized 10 nM of immunoligands while toxicity assays against BV173 
and SEM cell lines involving a dual-targeting triplebody (ULBP2-aCD19-aCD33) included 100 nM of 
immunoligands. Dual-activating triplebody (ULBP2-aCD19-aNKR) was not purified and crude 
concentrated S/N with undefined amount of triplebody was used for the experiments. Experiments 
confirming the role of NKG2D in immunoligand mediated toxicity involved pre-blocking of NKG2D 
receptor on purified NK cells by 20 µg/ml anti-NKG2D antibody (clone 1D11).  
For autologous cytotoxicity assay using patient’s innate NK:CLL ratio, PBMC were isolated from the 
peripheral blood of CLL patients similarly as described above for healthy donors. Percentage of NK, CLL 
and T cells were determined for each patient and accordingly PBMC were cultured in 96-well “U” 
bottom plates either alone or in presence of 10 nM ULBP2-aCD19-aCD19 for 48 hours. At the end of the 
incubation, cells were stained by AF647-labeled anti-CD20 and Pacific Blue-labeled anti CD5 antibodies. 
Fixed amount of counting beads (ThermoFisher, Cat Nr C36950) and 7-AAD dye were added in each 
sample and relative CLL cell count and 7-AAD-positive dead cells were determined by gating for 
CD20+/CD5+ CLL cells. 
Flow cytometry based NK cell degranulation assay was also performed additionally. Target cell line (See 
figure legend) and purified NK cells were co-incubated in “U” bottom 96-well plates at 2.5:1—E:T ratio 
with or without ULBP2-aCD19-aCD19 (10 nM) or ULBP2-aCD19-aCD33 (100 nM) for 6 hours. After 2 
hours of incubation, monensin (BioLegend) was added at a final concentration of 2 mM in every well and 
co-culture was continued for 4 hours. PE-labeled anti-human CD107a mAb was present in the medium 
throughout the 6 hours incubation period. At the end of the incubation, cells were stained with AF647-
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labeled anti-NKp46 and BV421-labeled anti-CD56 antibodies for 30 min on ice. Cells were then washed 
thrice with PBS containing 0.2 % BSA and 0.2 % NaN3 and were measured by flow cytometry. Gating on 
CD107a-positive cells within NKp46/CD56 double positive NK population revealed degranulated NK cells. 
4.5.3. NK cell IFNγ and TNFα secretion by immunoligands 
To detect the IFNγ secretion from NK cells in response to dual-targeting triplebody (ULBP2-aCD19-
aCD33) and its bispecific counterparts, purified and IL2 (200 U/ml) and IL15 (10 ng/ml) primed NK cells 
from healthy donors were cultured for 48 hours in 96 well MaxiSorp™ plates pre-coated with 10 µg/ml 
of immunoligands. In case of mono-targeting triplebody (ULBP2-aCD19-aCD19), purified NK cells were 
co-cultured with MEC1 cells in a 96 well “U” bottom plate at 1:1 (E:T) ratio in presence of 10 nM 
immunoligands for 24 hours. . After 48 or 24 hours respectively, S/N was collected by spinning down the 
cells in 500 µl eppendorf tubes and was frozen at -20°C until further use. Subsequently, SN was used to 
detect and measure IFNγ by ELISA (Human IFNγ ELISA MAX™ standard, Biolegend) according to 
manufacturer’s protocol. In brief, on day 1 MaxiSorp™ plate was coated with appropriately diluted 
capture antibody and was incubated at 4°C overnight. Next day, the plate was washed off the capture 
antibody and was blocked using assay diluent (1% BSA in PBS) for 1 hour at room temperature (RT). SN 
diluted 1:20 and 1:100 with assay diluent was incubated in appropriate wells for 2 hours at RT. After 
thorough washing, detection antibody and subsequently HRP-avidin was added to the wells. Finally, 1-
step™ Ultra TMB-ELISA substrate (ThermoFisher Scientific) was added to visualize the IFNγ bound 
antibody. Human IFNγ standard (500 pg/ml – 7.8 pg/ml) was used to quantify IFNγ in SN.              
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4.6. Animal study 
4.6.1. Role of ULBP2-aCD19-aCD19 in restriction of xenografted tumor growth in NSG 
mice  
21 five week old and female NOD scid gamma (NSG™) mice were purchased from Jackson laboratories 
and were maintained under sterile conditions. MEC1 cells were resuspended in Hank’s Buffered Salt 
Solution (HBSS) and 5 x 106 MEC1 cells in 100µl were injected subcutaneously (s.c.) into the flank of each 
mouse. This was considered as day 0. Following MEC1 cells engraftment, all 21 mice were randomly 
distributed within three groups (7 mice in each group). On day 2, PBMC were isolated from the buffy 
coats of healthy donors using Ficoll-Paques desnity gradient centrifugation as stated above. On the same 
day, each of the 7 mice in “Group 3” received freshly isolated 4 x 105 PBMC in HBSS + 15 µg ULBP2-
aCD19-aCD19 by a single intravenous (i.v.) injection into a tail vein. While, 3 mice within the “Group 2” 
received freshly isolated 4 x 105 PBMC in HBSS alone, the remaining 4 mice received freshly isolated 4 x 
105 PBMC in HBSS + 15 µg ULBP2-aPSMA. ULBP2-aPSMA was used as a non-relevant immunoligand as it 
is against Prostate-Specific Membrane Antigen (PSMA) which is absent from MEC1 cells, human PBMC 
population and mice tissue. This group served as a control for the group treated with PBMC + a mono-
targeting triplebody (ULBP2-aCD19-aCD19). The first group (7 mice) was left untreated and served as a 
control for the both treatment groups. Tumor development was measured periodically and the tumor 
volume was determined by the formula: (length x width x height)/2. The animals were sacrificed by 
cervical dislocation when the tumor volume reached 1,000 mm3 or at the end of the study period (until 
day 52) in case of no tumor sign. Animal experiments were approved from local authorities (State 
Northrhine-Westfalia, LANUV, approval no. 84-02.04.2012.A216).          
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4.7. Software and statistics 
FlowJo x was used to analyze the data of flow cytometry and imageJ was used to generate the confocal 
image. DNAstar was used to design cloning strategies and to analyze plasmid sequences. Microsoft 
office 2010 was used to prepare the figures and to write the thesis. Graphpad Prism 6 (San Diego, CA) 
was used for statistical analyses.  
Student’s t-test was used to compare two groups in NK cell functional assays in response to Schneider-2 
cells as target cells. Paired t-test was performed to compare two groups in NK cell functional assays in 
response to immunoligand against the same target cells. For comparisons involving three or more 
groups, one-way ANOVA test was performed and p values were corrected by Tukey’s multiple 
comparisons test. Kaplan–Meier survival at fixed time points was compared using log rank (Mantel–Cox) 
test. In all experiments, error bars are presented as standard error of the mean (SEM).  A two tailed p < 
0.05 indicated statistical significance and ns (not significant), p>0.05; *, p<0.05; **, p<0.05; ***, p<0.01.  
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5. Results 
5.1. NKG2D stimulation requires IL2 and IL15 priming for efficient execution of NK 
cell effector functions 
To assess the ability of NKG2D stimulation to facilitate NK cell activation and various effector functions, I 
used Drosophila Schneider-2 cells stably transfected with pAc5.1/V5-His_ULBP1 to express ULBP1 ligand 
on the cell surface. ULBP1 is one of several ligands for the activating receptor NKG2D on human NK cells 
as well as CD8+ T cells and γ/δ T cells. 
 
Figure 1. ULBP1 is expressed in Schneider-2 cells and localizes on the cell membrane. (A) ULBP1 
expression on Schneider-2 cells (WT or ULBP1 transfected) as detected by anti-ULBP1 (left) or 
NKG2D receptor. (B) Schneider-2 cells transfected by either empty GFP vector (left) or ULBP1-GFP 
fused vector (right) and visualizing ULBP1-GFP localization by confocal microscopy. 
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As shown in figure 1, ULBP1 expressed on Schneider-2 cells could be detected by flow cytometry using 
anti-ULBP1 antibody as well as recombinant human NKG2D receptor. Moreover, confocal images could 
further confirm the presence of ULBP1 (GFP-tagged) on the surface of Schneider-2 cells as opposed to 
diffused and cytoplasmic GFP expression in control transfection. The nature of glycosylation in 
Drosophila system is similar but not identical to mammalian glycosylation. Despite having a less complex 
glycosylation system, ULBP1 expressed in Schneider-2 cells was able locate to the cell surface and 
further to interact with NKG2D receptor, an important prerequisite for further functional assays.  
Using ULBP1 positive Schneider-2 (S2-ULBP1+) cells as target cells, important NK cell functions such as 
activation, degranulation and cytokine secretion were studied by flow cytometry (FACS). NK cells were 
purified by negative selection from PBMC of healthy blood donors and were pre-treated with different 
cytokines as indicated for each experiment. Figure 2 shows the gating strategies for such FACS based 
experiments using the Schneider-2 system or later, human cancer cell lines. At the end of the 
incubation, BV421-labeled anti-CD56 antibody was used to stain the typical NK cell marker CD56 in order 
to efficiently discriminate NK cells from broad types of target cells used in this thesis. First, the ability of 
ULBP1 expressing Schneider-2 cells to activate and degranulate resting NK cells was assessed. NK cells 
were considered as “resting” when purified NK cells were incubated with 10 U/ml IL2 overnight. IL2 at 
such low concentration only keeps primary NK cells alive and in healthy state but does not activate 
them. Upregulation of the activation marker CD69 on NK cells was checked after 6 hours of co-
incubation. The degranulation marker CD107a/LAMP-1 is exposed on the surface of NK cells for short 
duration when they degranulate and then is quickly re-internalized. Therefore, PE-labeled anti-CD107a 
antibody was present throughout the 6 hours of co-incubation to maximize the staining. Moreover, 2 
µM Monensin was added for the last 4 hours to prevent degradation of the CD107a-bound internalized 
anti-CD107a antibody. Figure 3 shows that NKG2D stimulation on resting NK cells by ULBP1 is not 
sufficient to activate or degranulate resting NK cells in 6 hours. 
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Figure 2. Flow cytometry based gating strategies to assess various NK cell effector functions. 
NK cells were purified from PBMC of healthy donors and were cultured in presence of 
cytokine(s) as indicated in each experiment. Next day, NK cells were co-incubated with the 
target cells for indicated duration. At the end of the incubation, NK cells were stained with 
BV421-labeled anti-CD56 antibody to discriminate them from target cells. Different markers 
were analyzed to assess various NK cell effector functions in response to particular target cells. 
(A) Upregulation of CD69 (stained by FITC-labeled anti-CD69) within CD56 positive NK cell 
population indicated activation of NK cells. Left: NKG2D stimulation on resting (IL2 10 U/ml 
primed) NK cells fails to activate them. Right: CD16 stimulation upregulates CD69 on 25% of 
the resting NK cells (B) Cell surface expression of CD107a/LAMP-1 on NK cells is an accurate 
marker to assess degranulation of NK cells. PE-labeled anti-CD107a staining within CD56 
positive NK cell population indicated degranulated NK cells. For example, NKG2D signaling on 
IL2 + IL15 primed NK cells leads to NK cell degranulation (right) in 23% of the population which 
was 6.49% in the absence of NKG2D signaling (left). (C & D) Intracellular staining of cytokines 
such as IFNγ and TNFα in fixed and permeabilized CD56-stained NK cells was performed. 
AF647-labeled anti IFNγ and FITC-labeled anti TNFα antibodies were used for the experiments. 
For example, NKG2D stimulation on IL2 + IL15 primed NK cells led to around 2-fold increase in 
both, IFNγ and TNFα positive NK cell population.   
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Purified NK cells were primed with IL2 (10 U/ml or 200 U/ml), IL12 (10 ng/ml), IL15 (10 ng/ml), IL18 (100 
ng/ml) or pair-wise combinations thereof for overnight to check whether this can prime NK cells to 
deliver effector functions in response to NKG2D stimulation. The NK cell degranulation assay was 
performed as described above; however, utilizing cytokine primed NK cells as effector cells (Figure 4). 
Increasing the concentration of IL2 from 10 U/ml (resting) to 200 U/ml did not enhance NK cell 
degranulation in response to S2-ULBP1+. Priming by IL12, IL15 or IL18 could significantly increase 
degranulating NK cell population in response to NKG2D stimulation when compared to wild-type (WT) 
Schneider-2 cells. Combination of IL2 with IL12, IL15 or IL18 cytokines did not have any additive effects 
in terms of degranulation. Although, pairwise combinations of IL12, IL15 and IL18 could significantly 
increase NK cell degranulation compared to WT Schneider-2 cells, these cytokines already provided the 
Figure 3. NKG2D stimulation on resting NK cells 
is not sufficient to activate or degranulate NK 
cells. Purified primary NK cells were incubated 
with IL2 (10 U/ml) for overnight and were 
considered as resting. The next day, NK cells 
were incubated with drosophila Schneider-2 
cells stably expressing ULBP1 (S2 + ULBP1) at 1:1 
E:T ratio for 6 hours. Wild type untransfected 
Schneider-2 cells were used as control in both 
experiments. NK cells were stained with anti-
CD56 antibody to discriminate between NK and 
Schneider-2 cells and activation and 
degranulation of NK cells was assessed by flow 
cytometry. (A) Induction of CD69 on CD56+ gated 
NK cells was used as a marker for activation of 
NK cells. (B) Induction of CD107a on CD56+ gated 
NK cells was used to assess the degranulated NK 
cell population. Error bars indicate standard 
error of the mean (SEM) and statistical analysis 
by Student’s t-test; N=3. For both experiments, 
each N represents an independent healthy NK 
cell donor 
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stronger priming signals to NK cells which was evident by high degranulation in response to WT target 
cells. 
 
Next, interleukin primed NK cells were also assessed for their ability to produce and secrete IFNγ and 
TNFα in response to NKG2D triggering by ULBP1. NK cells were co-incubated with target cells for 6 hours 
in presence of Brefeldin-A (last 4 hours) which blocks protein transport to the Golgi complex and rather 
Figure 4. NKG2D stimulation on cytokine primed NK cells leads to degranulation of NK cells in 
response to Schneider-2 cells expressing ULBP1. Purified primary NK cells were incubated with 
IL2 (10 U/ml or 200 U/ml), IL12 (10 ng/ml), IL15 (10 ng/ml), IL18 (100 ng/ml) or combinations 
thereof for overnight. On next day, NK cells were incubated with drosophila Schneider-2 cells 
stably expressing ULBP1 (S2 + ULBP1) at 1:1 E:T ratio for 6 hours. Wild type untransfected 
Schneider-2 cells were used as control in all experiments. NK cells were stained with anti-CD56 
antibody to discriminate between NK and Schneider-2 cells and degranulation of NK cells was 
assessed by flow cytometry. Induction of CD107a on CD56+ gated NK cells was used to assess the 
degranulated NK cell population. Error bars indicate standard error of the mean (SEM) and 
statistical analysis by Student’s t-test; N=3.  
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accumulates them in endoplasmic reticulum (ER). Detection of intracellular cytokines including IFNγ and 
TNFα can be enhanced when they accumulate in ER. Following 6 hours of incubation, cells were stained 
with BV421-labeled anti-CD56 antibody to detect NK cells. Cells were then fixed and permeabilized to 
enable intracellular staining of cytokines by AF647-labeled IFNγ and FITC-labeled TNFα antibodies in the 
same well. Depicted are the IFNγ (AF647+) and TNFα (FITC+) populations within NK cells (CD56+) based on 
the gating strategy shown in figure 2. 
 
Figure 5. NKG2D stimulation on cytokine primed NK cells leads to IFNγ secretion in response to 
Schneider-2 cells expressing ULBP1. Purified primary NK cells were incubated overnight with IL2 
(10 U/ml or 200 U/ml), IL12 (10 ng/ml), IL15 (10 ng/ml), IL18 (100 ng/ml) or combinations thereof. 
The next day, NK cells were incubated with S2-ULBP1+ at 1:1 E:T ratio for 6 hours. Untransfected 
wild type Schneider-2 cells were used as control in all experiments. NK cells were stained with anti-
CD56 antibody to discriminate between NK and Schneider-2 cells. Cells were fixed and 
permeabilized to stain intracellularly for IFNγ. Flow cytometry analysis identified IFNγ+ cells within 
the CD56+ gated NK cell population. Error bars indicate standard error of the mean (SEM) and 
statistical analysis by Student’s t-test; N=3. 
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Cytokine requirement for IFNγ and TNFα secretion upon NKG2D stimulation on NK cells was more 
stringent. As shown in figure 5, only IL15 or the combination of IL2 and IL15 could prime NK cells to 
secrete more IFNγ in response to NKG2D stimulation by S2 + ULBP1 (compared to WT Schneider-2 cells) 
which in case of IL2 + IL15 was also statistically significant. Similar to degranulation assay, pairwise 
combinations of IL12, IL15 and IL18 were activating themselves and could not be further enhanced by 
NKG2D stimulation.  
 
Figure 6(A) shows that ULBP1-NKG2D axes induced TNFα secretion by IL15 or IL2 + IL15 primed NK cells 
was increased compared to that by wildtype target cells but was not significant. This assay was repeated 
with 3 independent NK cell donors and 2 out of which showed almost 2-fold increase in TNFα secretion 
Figure 6. NKG2D stimulation on cytokine primed NK cells leads to TNFα secretion in response to 
Schneider-2 cells expressing ULBP1.  (A) Purified primary NK cells were incubated with IL2 (10 U/ml 
or 200 U/ml), IL12 (10 ng/ml), IL15 (10 ng/ml), IL18 (100 ng/ml) or combinations thereof for 
overnight. On next day, NK cells were incubated with drosophila Schneider-2 cells stably expressing 
ULBP1 (S2-ULBP1+) at 1:1 E:T ratio for 6 hours. Wild type untransfected Schneider-2 cells were used 
as control in all experiments. NK cells were stained with anti-CD56 antibody to discriminate 
between NK and Schneider-2 cells. Cells were fixed and permeabilized to stain intracellularly for 
TNFα. TNFα+ cells in CD56+ gated NK cells indicated NK cell population that secreted TNFα by flow 
cytometry. Error bars indicate standard error of the mean (SEM) and statistical analysis by 
Student’s t-test; N=3. (B) IL2 + IL15 primed NK cells from 2 out of 3 donors showed 2-fold increase 
in TNFα positive NK cells in response to S2 + ULBP1. Error bars indicate standard error of the mean 
(SEM); N=2.   
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at least by IL2 + IL15 primed NK cells (Figure 6(B)) suggesting donor dependent variability. Taken 
together, cytokine requirement for NKG2D-dependent NK cell degranulation was less stringent 
compared to IFNγ secretion and was most stringent for TNFα secretion. However, IL15 or combination 
of IL2 + IL15 could prime NK cells most efficiently to respond to NKG2D stimulus. 
5.2. A mono-targeting triplebody ULBP2-aCD19-aCD19 enhances NK cell dependent 
killing of CLL cell line – MEC1 
Successful cloning of pL(ULBP2-aCD19), pL(ULBP2-aCD19-aCD19) and pL(aCD19scFv) was confirmed by 
restriction digestions and sequencing of the complete reading frame. All of these three constructs were 
transfected into HEK293T cells and stable clones were selected with Zeocin™ as the plasmids also 
expressed Zeocin-resistance gene.  Stable clones (polyclonal) were subsequently cultured in serum free 
CD293 medium and SN was collected every 2-3 days over a period of a month. As shown in figure 7(A), 
triplebody ULBP2-aCD19-aCD19 and bispecific counterpart ULBP2-aCD19 carried ULBP2 in front and the 
N-terminal sequence of ULBP2 facilitated secretion of both of these immunoligands into the SN of 
transfected cells. In contrast, Igκ leader sequence was placed 3’ of the control construct (aCD19scFv) to 
facilitate its secretion. A Gly/Ser linker of total 20 amino acids—(GGGGS)4x was used to link each moiety 
(figure 7(A)) as well as VH and VL domains of an scFv (not shown in the figure) to confer flexibility to the 
immunoligands. All three constructs consisted of a 6xHis (HHHHHH) tag at the C-terminus, which was 
used for purification. While U-19 and U-19-19 carried a c-Myc tag for detection purpose, it was omitted 
from a blocking construct aCD19scFv. Between 400 µg to 700 µg of U-19 and U-19-19 and around 1 mg 
of aCD19scFv was purified from around 1 liter of cell culture SN. Figure 7(B) shows that the purified 
immunoligands were of high purity, expected size and monomeric in nature as verified by c-Myc tag 
specific immunoblotting (left) and coomassie staining (right). U-19 and U-19-19 had the expected 
molecular weight of 64 kDa and 91 kDa, respectively. Purity and size for a blocking construct aCD19scFv 
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were also verified by coomassie staining (data not shown). It was found to be of high purity and 
according to the expected molecular weight. 
 
Once the immunoligands were purified with high purity, next was the assessment for their binding 
ability and specificity. Both aspects are important prerequisites for further functional testing and 
preclinical development. A CD19+ CLL cell line MEC1 was used for this evaluation. MEC1 cells were 
incubated with ULBP2-aCD19 and ULBP2-aCD19-aCD19 at 10 µg/ml concentration and its binding was 
subsequently detected by c-Myc tag specific antibody or recombinant NKG2D receptor (Fc tag fused). 
Figure 7. Schematic representation and expression of a mono-targeting triplebody ULBP2-
aCD19-aCD19 and bisepcific counterpart ULBP2-aCD19. (A) Cartoon illustrating bispecific 
immunoligand ULBP2-aCD19 (U-19) and triplebody ULBP2-aCD19-aCD19 (U-19-19) as well as a 
control construct: aCD19scFv. (B) All constructs were expressed in eukaryotic cell line HEK293T 
and purified from the supernatant by affinity chromatography utilizing their 6xHis tag. U-19 and U-
19-19 immunoligands were separated on SDS-PAGE for protein gel or blot staining using anti c-
Myc tag antibody (left) or coomassie staining (right) to confirm the size and purity. Coomassie 
staining was also done to check the size and purity of the control construct aCD19scFv (Data not 
shown). Data shown in figure was previously published in Vyas et al., 2016. 
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Both, ULBP2-aCD19 and ULBP2-aCD19-aCD19 bound to MEC1 cells and this binding was specific to CD19 
antigen as pre-blocking of CD19 antigen by aCD19scFv construct completely blocked the binding of 
immunoligands as depicted as dotted line in histograms (figure 8). 
 
Specificity was further proven as both immunoligands failed to bind to HL60 cell line, which is CD19 
antigen negative (figure 8). Detection of immunoligands by NKG2D-Fc receptor also confirmed that both, 
ULBP2-aCD19 and ULBP2-aCD19-aCD19 are able to bind simultaneously to both of their target moieties 
Figure 8. ULBP2-aCD19-aCD19 and ULBP2-aCD19 binds specifically and simultaneously to both 
target antigens CD19 and NKG2D. Binding of both immunoligands (10 µg/ml) to CD19+ MEC1 cells 
was detected indirectly by anti-Myc tag antibody (upper panel “C-Myc-tag” - MEC1) and by 
recombinant human NKG2D-Fc receptor (lower panel “NKG2D-Fc” - MEC1). Specificity of both 
immunoligands to CD19 was confirmed by pre-blocking of CD19 antigen by a blocking construct 
aCD19scFv (20 µg/ml) as depicted by dotted line and also by performing binding assays with CD19 
negative cell line HL60 (right column – “HL60”). Data shown in figure was previously published in 
Vyas et al., 2016. 
 
51 Results 
(CD19 antigen and NKG2D receptor) and therefore will be able to crosslink CLL and NK cells. Binding of 
immunoligands to coated NKG2D receptor additionally assured that they can bind to NKG2D receptor 
specifically as pre-blocking of NKG2D receptor by a blocking antibody (anti-NKG2D, clone 1D11) 
abolished the signal (figure 9). 
 
Following specific and simultaneous binding of immunoligands, I wanted to investigate their functional 
activity and tested whether they can also enhance NK cell-dependent killing of the CLL cell line MEC1. 
Another specific aspect of utmost interest was to check, whether addition of a second antiCD19 scFv to 
the bispecific ULBP2-aCD19 confers any advantage in terms of target cell killing. For this set of 
Figure 9. ULBP2-aCD19-aCD19 and ULBP2-aCD19 binds 
specifically to recombinant human NKG2D receptor. 
Recombinant human NKG2D-Fc receptor was coated on 
MaxiSorp plate (100 ng per well) and binding of ULBP2-aCD19 
and ULBP2-aCD19-aCD19 (both, 10 µg/ml) to the receptor was 
detected using HRP-labeled anti Myc antibody. Pre-blocking of 
coated NKG2D-Fc receptor was done by anti-NKG2D antibody 
(clone 1D11; 20 µg/ml). Error bars indicate standard error of the 
mean (SEM); N=3. Experiment was done in duplicates and each N 
represents an independent experiment.  
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experiments, NK cells were purified from PBMC of healthy donors, primed with IL2 (200 U/ml) and IL15 
(10 ng/ml) and were then used as effector cells in a FACS based toxicity assay. NK cell preparations from 
different donors were routinely stained for surface markers to characterize NKG2D expression, NK cell 
activation status (CD69 expression) and purity (by CD56 and CD16 co-expression as well as NKp46 
expression) and preparations with ≥ 98% purity were used for experiments. NK cells were co-incubated 
with DiR-labeled MEC1 cells at indicated effector to target (E:T) ratios and 7-AAD was used to 
discriminate live and dead cells (figure 10(A)). Both immunoligands at 10 nM concentration could 
significantly enhance NK cell dependent killing of CD19+ MEC1 cells in an E:T ratio dependent manner. 
This toxicity was not seen against CD19- HL60 cells, which suggested that this effect was antigen specific 
and immunoligands did not induce NK cell degranulation in (target cell) unbound state (figure 10(B)). 
Interestingly, at all E:T ratios, mono-targeting triplebody (ULBP2-aCD19-aCD19) induced killing of MEC1 
cells was higher compared to the bispecific counterpart (ULBP2-aCD19). When NKG2D receptor was 
blocked (by anti-NKG2D antibody, clone 1D11) on NK cells prior to the toxicity assay, triplebody failed to 
induce any killing of MEC1 cells (figure 10(C)). In addition, NKG2D blocking also lowered the background 
killing of MEC1 cells by NK cells. This was most likely because it blocked the interaction between the 
endogenous ligands for NKG2D receptor on MEC1 cells and NKG2D receptor on NK cells. 
Figure 10. Enhancement of NK cell dependent killing of MEC1 cells by a mono-targeting triplebody ULBP2-
aCD19-aCD19. (A) Gating strategy for flow cytometry based toxicity assay. Target cells (MEC1) were labeled 
with DiR and were incubated with purified IL2 + IL15 primed NK cells either alone or in presence of 10 nM 
triplebody or bispecific ULBP2-aCD19 at various E:T ratios (left). The incubation was continued for 3 hours and 
7-AAD was added to detect dead cells within the DiR positive gate (right). (B) NK cells were incubated with 
CD19+ MEC1 cells or CD19- HL60 cells at 0.612:1, 1.25:1 and 2.5:1 E:T ratios. Both immunoligands enhanced the 
NK cell dependent killing of antigen positive MEC1 cells but not of antigen negative HL60 cells in E:T ratio 
dependent manner. Error bars indicate standard error of the mean (SEM) and statistical analysis by One-way 
ANOVA; N=4 (MEC1) and N=3 (HL60). Each N represents an independent healthy NK cell donor. (C) 
Immunoligand mediated killing of MEC1 cells is via NKG2D receptor on NK cells. NK cells were incubated with 
10 µg/ml of mouse anti-human NKG2D receptor antibody (clone 1D11) or mouse isotype control (IgG1) for 30 
min on ice. Excess antibody was washed away after 30 min and toxicity assay was setup as described above. 
Error bars indicate standard error of the mean (SEM) and statistical analysis by Paired t-test; N=3. * represents 
P < 0.05. Data shown in figure was previously published in Vyas et al., 2016. 
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Figure 10. Enhancement of NK cell dependent killing of MEC1 cells by a mono-targeting 
triplebody ULBP2-aCD19-aCD19. (Figure legend on previous page)  
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NK cell cytotoxicity was also independently assessed by FACS based degranulation assay against MEC1 
cells. In line with the toxicity assay, ULBP2-aCD19-aCD19 could increase the degranulating NK cell 
population up to 1.5-fold in response to MEC1 (figure 11(B)). In addition, the ability of ULBP2-aCD19-
aCD19 to induce IFNγ production was assessed in IL2 and IL15 primed NK cells. IFNγ release into the 
supernatant was measured following 24 hours co-culture of NK and MEC1 cells, either alone or in 
presence of 10 nM immunoligands at an E:T ratio of 1:1. Assessment with two independent NK cell 
donors showed comparable enhancement of IFNγ production by NK cells by ULBP2-aCD19 and ULBP2-
aCD19-aCD19 (one representative shown; figure 11(A)). A blocking construct aCD19scFv failed to induce 
IFNγ production indicating that immunoligands required ULBP2 for this effect. Co-incubation in absence 
of any construct served as a control. IFNγ secretion by MEC1 cells (with or without immunoligand) was 
carefully controlled and was found to be negative (data not shown). 
 
Figure 11. ULBP2-aCD19-aCD19 and ULBP2-
aCD19 enhances NK cell effector functions in 
response to target cell line MEC1. (A) IL2 + IL15 
primed NK cells were co-incubated with MEC1 
cells at 1:1 (E:T) ratio in presence of 10 nM 
immunoligands for 24 hours. SN was collected 
and was used to quantify IFNγ by ELISA. Error 
bars indicate standard error of the mean (SEM) of 
duplicates. Experiments were conducted with 
two independent NK donors and one example is 
shown here. (B) IL2 + IL15 primed NK cells were 
co-incubated with MEC1 cells in 2.5:1 (E:T) ratio 
in presence of 10 nM ULBP2-aCD19-aCD19 or 
alone for 6 hours and CD107a+ cells within CD56+ 
NK cells indicated degranulated NK cells by flow 
cytometry. Error bars indicate standard error of 
the mean (SEM) and statistical analysis by Paired 
t-test; N=3. Data shown in figure was previously 
published in Vyas et al., 2016. 
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5.3. ULBP2-aCD19-aCD19 mediates NK cell dependent killing of primary CLL cells in 
allogeneic setting  
Figure 12. Enhancement of NK cell dependent killing of primary CLL cells by a mono-targeting 
triplebody ULBP2-aCD19-aCD19 in allogeneic setting. (Figure legend on next page)  
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Following encouraging results with MEC1 cell line, toxicity assays were also performed in both allogeneic 
and autologous settings using malignant B cells from CLL patients. In allogeneic experiments, purified NK 
cells from healthy unrelated (to CLL patients) blood donors were used as effector cells while target cells 
comprised of freshly isolated malignant B cells from CLL patients. Apart from that, the general protocol 
and FACS gating strategy was similar to MEC1 toxicity assays.  
In allogeneic experiments, presence of ULBP2-aCD19-aCD19 increased NK-cell-dependent killing of 
primary CLL cells from early (Binet A—Pt #1) and late stage (Binet C—Pt #2) CLL patients in the range of 
1.5-fold–2-fold at all E:T ratios (figure 12(A)). Due to high donor-dependent variability, percentage killing 
of CLL cells by immunoligands were standardized to the background NK cell mediated killing of CLL cells 
in that particular experiment to generate x-fold increase in CLL killing. As shown in figure 12(B), 
cumulative analysis of four CLL patients (including Pt #2) showed that the effect mediated by ULBP2-
aCD19-aCD19 was significantly higher than background killing (NK) at all but one E:T ratio (1.25:1). Even 
in these allogeneic experiments, ULBP2-aCD19-aCD19 showed higher NK-cell-dependent killing of CLL 
cells than ULBP2-aCD19, which, although not significant, is in line with the previous results with MEC1 
cell line. 
 
Figure 12. Enhancement of NK cell dependent killing of primary CLL cells by ULBP2-aCD19-aCD19 
and ULBP2-aCD19 in allogeneic setting. (A) Purified and IL2 + IL15 primed NK cells from healthy 
donors were co-incubated with DiR labeled primary CLL cells either alone or in presence of 10 nM 
indicated immunoligands. The incubation was continued for 3 hours and dead CLL cells were 
measured by 7-AAD staining on FACS. Two representative results from Binet A and C stage CLL 
patients (Pt #1 and Pt #2) are shown from total five independent experiments with different CLL 
patients. NK cells for each experiment were obtained from different healthy donors. (B) Data from 
total 4 independent tox assays were used for statistical evaluation at each E:T ratio. Error bars 
indicate standard error of the mean (SEM) and statistical analysis by One-way ANOVA (*P < 0.05; 
**P < 0.01). N= 4 where each N represents an independent CLL patient and healthy NK cell donor. 
Data shown in figure was previously published in Vyas et al., 2016. 
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5.4. ULBP2-aCD19-aCD19 overcomes soluble inhibitory factors in the serum of CLL 
patients 
Figure 13. ULBP2-aCD19- aCD19 overcomes the inhibitory effects of CLL serum samples to enhance NK cell 
dependent killing of MEC1 cell. (A) The toxicity assay was carried out in presence of 20% serum from 
indicated CLL patients or same volume of IMDM medium. Dead cells were measured by 7-AAD staining in DiR 
positive target cells after 3 hours of co-incubation. The serum from CLL Pt #3 (Binet B) contained 537 pg/ml 
and from CLL Pt #4 (Binet C) contained 670 pg/ml soluble NKG2D ligands. E:T ratio written at top of each bar. 
(B) ULBP2-aCD19-aCD19 induced killing of MEC1 cells was normalized to the background killing by NK cells to 
calculate ULBP2-aCD19-aCD19 specific x-fold killing of MEC1 cells. Data shown in figure was previously 
published in Vyas et al., 2016. 
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Serum from CLL patients contains high levels of soluble ligands for NK cell receptors as well as other 
soluble immune-inhibitory factors that can counteract any NK cell therapeutic approach. For example, 
soluble ligands for NKG2D can block this receptor and in turn prevent triplebody to bind and recruit NK 
cells. Therefore, toxicity assays were performed in presence of serum from CLL patients to check if 
ULBP2-aCD19-aCD19 can overcome the inhibition to mediate NK cell dependent killing of MEC1 cells 
(figure 13). 
IL2 and IL15 primed NK cells from healthy donors were used with MEC1 cells in a 3 hour toxicity assay in 
absence or presence of 20% serum from two CLL patients. The serum from CLL Pt #3 (Binet B) contained 
537 pg/ml soluble NKG2D ligands (ULBP2 – 12 pg/ml; MICA – 525 pg/ml); and from CLL Pt #4 (Binet C) 
contained 670 pg/ml soluble NKG2D ligands (MICB – 89 pg/ml, ULBP2 – 41 pg/ml; MICA – 540 pg/ml). It 
is possible that these serum samples also contained other NKG2D ligands or other inhibitory factors that 
were not quantified. As shown in figure 13(A), background killing of MEC1 cells by NK cells (No 
construct/immunoligand) was also reduced for all E:T ratios by serum from CLL pt #3 (Binet B) and even 
further by serum from CLL pt #4 (Binet C). Presence of ULBP2-aCD19-aCD19 could still enhance NK cell 
dependent killing of MEC1 cells in each group despite the presence of soluble NKG2D ligands and other 
inhibitory factors in serum samples from CLL patients which is further clarified in figure 13(B). 
Normalized values show that at higher NK:MEC1 ratios (2.5:1 and 1.25:1), triplebody induced MEC1 
killing in presence of serum samples was in similar range to the control group, however, at E:T – 0.612:1, 
triplebody induced MEC1 killing was higher in presence of serum from both patients compared to 
without serum. Of note, this was due to stronger inhibition of NK cell mediated background killing rather 
than higher triplebody-specific killing at 0.612:1 ratio. 
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5.5. ULBP2-aCD19-aCD19 mediates NK cell dependent killing of primary CLL cells in 
autologous setting 
In allogeneic setting, killer cell immunoglobulin-like receptors (KIR) mismatch between donor NK and 
patient CLL/MEC1 cells can contribute towards NK cell dependent target cell killing. In autologous 
setting, patient NK cells are less responsive towards the cancer cells from the same patient due to 
complete KIR matching. In addition, whether NK cells in CLL patients express NKG2D receptor and if 
these can be primed by IL2 and IL15 cytokines were two major concerns for feasibility of my therapeutic 
approach.  
 
 
Figure 14. NK cells from CLL patients 
(N=5) express NKG2D receptor that can 
be upregulated by IL2 and IL15 priming. 
PBMC from CLL patients were incubated 
overnight either in presence of IL2 (200 
U/ml) or IL2 (200 U/ml) + IL15 (10 ng/ml) 
or were left untreated (No cytokine) and 
on next day NKG2D receptor expression 
was assessed. (A) 5 CLL patients included 
2 Binet A (Pt #5 and Pt #6) and 3 Binet B 
(Pt #7, Pt #8 and Pt #9) stage patients. (B) 
Due to varying expression levels, 
cumulative analysis for all 5 CLL patients 
for x-fold NKG2D expression normalized 
to control group is shown. Error bars 
indicate standard error of the mean (SEM) 
and statistical analysis by One-way 
ANOVA where * represents P < 0.05; ** 
represents P < 0.01; *** represents P < 
0.001. Data shown in figure was 
previously published in Vyas et al., 2016. 
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To test this, PBMC from 5 CLL patients (at Binet A and B stages) were stained with AF647-labeled anti-
NKp46 and FITC-labeled anti-NKG2D antibodies to assess the expression level of NKG2D receptor on NK 
cells (figure 14). While, NK cells from all CLL patients expressed NKG2D endogenously at varying level, 
overnight incubation with IL2 alone significantly upregulated NKG2D expression on NK cells from all CLL 
patients (p=0.03). Combination of IL2 + IL15 further enhanced the NKG2D expression on NK cells 
compared to “no cytokine” (p=0.0001) and IL2 alone (p=0.0002) groups. Similarly, NKG2D expression on 
CD8 T cells was also found to be upregulated by IL2 + IL15 (data not shown). 
These findings encouraged to study whether ULBP2-aCD19-aCD19 can overcome KIR inhibition to 
retarget patient’s own effector cells against tumor cells in autologous setting. First, toxicity assays in 
autologous setting were performed utilizing patient’s innate or unaltered NK to CLL (E:T) ratio. PBMC 
were isolated from peripheral blood of CLL patients and were stained by AF647-labeled anti-NKp46 (NK 
cells), PB-labeled anti-CD3 (T cells) and AF647-labeled anti-CD20 + PB-labeled anti-CD5 (CLL cells) 
antibodies to characterize NK, T and CLL cell populations. For example, of total two analyzed Binet A 
patients in this study, Pt #10 had higher percentage of NK and T cells (3.61% and 15.5%) compared to Pt 
#11 (NK: 0.81% and T: 4.28%), shown in figure 15(A).  This led to the different endogenous NK:CLL ratio 
in both patients with 0.05:1 – NK:CLL in Pt #10 and 0.009:1 – NK:CLL in Pt #11. For toxicity assay, PBMC 
from both CLL patients were cultured alone or in presence of 10 nM ULBP2-aCD19-aCD19 for 48 hours 
and absolute CLL count was calculated at the end of the incubation. Dead CLL cells were excluded by 
addition of 7-AAD dye. Figure 15(B) shows that in correlation with innate NK:CLL ratio, Pt #10 (with 
higher NK:CLL ratio) had lower viable CLL cells compared to Pt #11 (with lower NK:CLL ratio) and this also 
correlated with higher 7-AAD positive (dead) CLL cells in Pt #10 then in Pt #11 (shown in figure 15(C)). 
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Figure 15. ULBP2-aCD19-aCD19 induced and autologous NK cell mediated killing of CLL cells 
depends on endogenous NK:CLL ratio. (Figure legend on next page)  
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Figure 16. ULBP2-aCD19-aCD19 enhanced 
autologous NK cell mediated killing of CLL 
cells in effector to target ratio dependent 
manner. NK cells were purified by negative 
selection from PBMC of both patients and 
were primed with IL2 + IL15 overnight. The 
following day, NK cells were co-incubated 
with DiR-labeled purified CLL cells from the 
same patient for 3 hours either alone or in 
presence of 10 nM ULBP2-aCD19-aCD19 
and dead CLL cells were analyzed by 7-AAD 
gating. For both patients, triplebody 
enhanced NK cell dependent killing of CLL 
cells with increase in NK:CLL ratio. Data 
shown in figure was previously published in 
Vyas et al., 2016.            
Figure 15. ULBP2-aCD19-aCD19 induced and autologous NK cell mediated killing of CLL cells 
depends on endogenous NK:CLL ratio. (A) PBMC were isolated from peripheral blood of CLL 
patients and were stained by anti-NKp46 (NK cells), anti-CD3 (T cells) and anti-CD20 + anti-CD5 (CLL 
cells) antibodies to characterize NK, T and CLL cell populations. Both CLL Binet A patients, Pt #10 and 
Pt #11, had varying innate NK:CLL ratios (0.05:1 and 0.009:1, respectively). Isolated PBMC were 
incubated alone or in presence of 10 nM ULBP2-aCD19-aCD19 for 48 hours and absolute CLL cell 
count was measured. In addition, 7-AAD was added to exclude any dead cells (Gating strategy in (B) 
and results shown in (C)). Error bars indicate standard error of the mean (SEM) of duplicates. Data 
shown in figure was previously published in Vyas et al., 2016. 
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Next, NK cells were purified from the peripheral blood of the same patients (Pt #10 and Pt #11), were 
primed overnight IL2 and IL15 and were incubated with purified malignant B cells from the same 
patients to test the effect of the triplebody. The main idea was to check whether increasing the innate 
NK:CLL ratio can improve the triplebody mediated killing of CLL cells. Presence of ULBP2-aCD19-aCD19 
enhanced NK cell dependent killing of CLL cells from both patients in merely 3 hours despite KIR 
inhibition. The killing capacity became more evident with increase in NK cell proportion and Pt #11 
which was resistant to triplebody induced NK cell response during earlier toxicity assay now turned 
susceptible. 
5.6. ULBP2-aCD19-aCD19 shows promising anti-tumor activity in immuno-deficient 
mouse model (NSG)  
Finally, the ability of ULBP2-aCD19-aCD19 to restrict tumor growth was assessed in MEC1 xenografted 
immunodeficient mice. In total 21 female NOD scid gamma (NSG™) mice, aged around 5-6 weeks, were 
utilized in this study. NSG strain carries severe combined immunodeficiency (scid) and IL2 receptor 
deficiency on NOD/ShiLtJ background and is the most immunodeficient strain described to date. The 
NOD/ShiLtJ background already represents reduced innate immune system to which Prkdcscid or scid 
mutation results in almost complete elimination of mature B and T cells (adaptive immune system). The 
null mutation in IL2 receptor gamma chain (IL2Rγ) completely blocks NK cell differentiation and enables 
efficient engraftment of xenografts.  
Figure 17(A) shows the experimental plan and time line of the study. On day 0, MEC1 cells (5 x 106) were 
injected into the flank of all 21 NSG mice by a subcutaneous (s.c.) injection and mice were randomly 
distributed into 3 groups. Two days later, 4 x 105 PBMC (freshly isolated from a healthy donor) together 
with 15 µg of ULBP2-aCD19-aCD19 were transplanted intravenously (tail vein) in 7 mice. The control 
group consisting of 7 mice was left untreated. Remaining 7 mice in the second group were further 
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divided in two groups and 4 out of 7 mice were treated with 4 x 105 PBMC alone while 3 mice were 
treated with 4 x 105 PBMC along with 15 µg of ULBP2-aPSMA (non-relevant immunoligand). However, 
for initial analysis (figure 17), both subgroups (4 + 3 mice) were combined in the same group considered 
as a “PBMC ± U-PSMA” control group. Tumor growth was monitored by measuring the tumor volume 
regularly until the end of the study on day 52.  
 
Figure 17. ULBP2-aCD19-aCD19 restricts tumor growth in MEC1 xenotransplanted NOD™ scid 
gamma (NSG) mice. (A) Subcutaneous engraftment of MEC1 cells to 21 NSG mice on day 0 followed 
by human PBMC transplantation alone or together with ULBP2-aPSMA (non-relevant 
immunoligand) (7 mice); or together with 15 µg of ULBP2-aCD19-aCD19 (7 mice). Tumor growth 
was monitored regularly until the end of the study on day 52. (B) Tumor growth was assessed by 
measuring the tumor size on each mouse at regular intervals using the formula for tumor volume (L 
x W x H/2). The graph shows the measurements until day 28 which was the last time point when all 
21 mice were alive. Error bars indicate standard error of the mean (SEM) and statistical analysis by 
one-way ANOVA, N=7 in each group. For simplicity, statistical significance between “No treatment” 
and “PBMC + U-19-19” groups are shown. (*p < 0.05; **p < 0.01). (C) During the total duration of 
the study (52 days), mice were sacrificed when the tumor volume reached 1,000 mm3. Data shown 
in figure was previously published in Vyas et al., 2016.   
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Figure 17(B) compares the mean of tumor volume in each group until day 28 as this was the last day 
when all 21 mice were alive and 2 mice in the control “no treatment” group had to be sacrificed after 
this time point due to tumor volume larger than 1,000 mm3. The tumor occurrence was first observed in 
7 mice in “no treatment” group, while the PBMC transplantation, either alone or with an irrelevant 
construct (PBMC + U-PSMA), delayed the tumor occurrence in “PBMC ± U-PSMA” group. However, the 
tumor growth between both control groups (“no treatment” and “PBMC ± U-PSMA”) was not 
significantly different at any given time point. On the other hand, transplantation of PBMC with ULBP2-
aCD19-aCD19 (PBMC + U-19-19) completely restricted the tumor occurrence in these mice and this 
effect was significant compared to the “no treatment” group. 
According to ethical regulations, mice were sacrificed upon the tumor volume reaching 1,000 mm3. The 
study was continued for 52 days and as shown in figure 17(C) all mice in both “no treatment” and 
“PBMC U-PSMA” groups had to be sacrificed due to large tumor volume while all 7 mice treated with 
ULBP2-aCD19-aCD19 remained tumor free and were censored at the end of the study. Kaplan Meier 
survival curve of “PBMC + U-19-19” group was significantly different from “PBMC ± U-PSMA” (p = 
0.0003) and “No treatment” group (p = 0.0002) while there was no significant difference between 
“PBMC ± U-PSMA” and “no treatment” groups (p = 0.568). (Two tailed p value < 0.0167 was considered 
as significant; 0.0167 was Bonferroni-corrected threshold). 
Interestingly, the initial tumor growth among mice treated with PBMC alone or along with a non-
relevant immunoligand ULBP2-aPSMA showed discrepancy. The tumor occurrence and initial 
progression in 3 mice treated with PBMC + ULBP2-aPSMA was delayed compared to 4 mice treated with 
PBMC alone (figure 18(A)). This was surprising as ULBP2-aPSMA immunoligand was not expected to 
retarget NK cells to PSMA negative transplanted human cells (PBMC or MEC1). However, in the 
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following weeks tumor started progressing rapidly in all 3 mice in “PBMC + U-PSMA” group and took 
similar duration to reach 1,000 mm3 compared to 4 mice in “PBMC” group (figure 18(B)). 
 
5.7. A dual-targeting triplebody ULBP2-aCD19-aCD33 can simultaneously bind to all 
three target antigens and retains specificity for antigen loss variants 
Expression vectors pL(ULBP2-aCD19-aCD33), pL(ULBP2-aCD33) and pL(aCD33scFv) were successfully 
cloned and complete reading frame was sequenced. Expression vectors for CD19 targeting bispecific 
counterpart (pL(ULBP2-aCD19)) and blocking construct (pL(aCD19scFv)) were generated for CLL project 
and is described previously in section 2 of results. Similar to previous constructs, three new constructs in 
this project were also transfected into HEK293T cells and stable clones were selected with Zeocin™ as 
the plasmids also expressed Zeocin-resistance gene. Stable clones (polyclonal) were subsequently 
Figure 18. Mice treated with PBMC + a non-
relevant ULBP2-aPSMA showed delayed onset 
followed by rapid progression of transplanted 
tumor. (A) Delayed onset of tumor in “PBMC + 
U-PSMA” group. Tumor measurement on day 32 
revealed that 3 mice treated with PBMC + 
ULBP2-aPSMA had delayed onset of tumor 
compared to 4 mice treated with PBMC alone 
even though ULBP2-aPSMA was a non-specific 
immunoligand. (*p < 0.05; **p < 0.01). (B) Rapid 
tumor progression in “PBMC + U-PSMA” group. 
Despite late onset, tumor in all 3 mice of “PBMC 
+ U-PSMA” group progressed much quicker and 
did not take significantly longer time to reach 
1,000 mm3 size compared to 4 mice in “PBMC” 
group. (*p < 0.05; **p < 0.01). Error bars 
indicate standard error of the mean (SEM) and 
statistical analysis by one-way ANOVA. Data 
shown in figure was previously published in 
Vyas et al., 2016. 
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cultured in serum free CD293 medium and SN was collected every 2-3 days over a period of month. As 
shown in figure 19(A), triplebody ULBP2-aCD19-aCD33 and bispecific counterpart ULBP2-aCD33 were 
secreted into the SN of transfected cells by innate secretion signal carried at the N-terminus of ULBP2. In 
contrast, secretion of a blocking construct aCD33scFv was enabled by Igκ leader sequence at the N-
terminus. A Gly/Ser linker of total 20 amino acids—(GGGGS)4x was used to link each moiety (figure 
19(A)) as well as VH and VL domains of an scFv (not shown in the figure) to confer flexibility to the 
immunoligands. C-terminus 6xHis (HHHHHH) tag was used for purification of all constructs while an 
additional c-Myc tag at the C-terminus of U-33 and U-19-33 was used for their detection purposes. 
Between 400 µg to 700 µg of U-33 and U-19-33 and around 1 mg of aCD33scFv was purified from 
around 1 liter of the culture SN.  
 
 
 
 
 
 
 
 
 
 
Figure 19. Schematic representation and expression of a dual-targeting 
triplebody ULBP2-aCD19-aCD33 and bispecific counterparts ULBP2-aCD19 
and ULBP2-aCD33. (A) Cartoon illustrating bispecific immunoligand ULBP2-
aCD33 (U-33) and triplebody ULBP2-aCD19-aCD33 (U-19-33) as well as a 
control construct: aCD33scFv. (B) U-19, U-33 and U-19-33 immunoligands 
were separated on SDS-PAGE for protein gel blot staining using anti c-Myc 
tag antibody (left) or coomassie staining (right) to confirm the size and 
purity. Data shown in figure was previously published in Vyas et al., 2016. 
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Once purified, immunoligands were separated by SDS-PAGE for c-Myc tag specific immunoblotting 
(figure 19(B), left) and coomassie staining (figure 19(B), right). Triplebody U-19-33 and bispecific 
immunoligands U-19 and U-33 were found to be pure, according to the expected molecular weight and 
monomeric in nature. U-19 and U-33 had the expected molecular weight of ≈64 kDa and ≈58 kDa and U-
19-33 was, as expected, of ≈89 kDa, respectively. Purity and molecular weight for blocking constructs 
aCD19scFv and aCD33scFv were also verified by coomassie staining (data not shown). 
 
Figure 20. ULBP2-aCD19-aCD33 and bispecific counterparts ULBP2-aCD19 and ULBP2-aCD33 bind specifically 
to the respective target antigens. (A) Incubation of 10 µg/ml immunoligands with CD19+/CD33+ BV173 cell line 
as detected by recombinant NKG2D-Fc receptor (left graph). Pre-blocking of CD19 or CD33 antigens by 
aCD19scFv or aCD33scFv blocking constructs (both at 20 µg/ml) completely inhibited the binding of respective 
bispecific immunoligands (right graph). (B) Blocking of either CD19 or CD33 antigens by aCD19scFv or 
aCD33scFv (20 µg/ml) reduces the binding of a dual-targeting triplebody ULBP2-aCD19-aCD33, but does not 
abolish it (left graph). Binding can only be completely abrogated by pre-blocking of both CD19 and CD33 
antigens simultaneously (right graph). Data shown in figure was previously published in Vyas et al., 2016. 
 
69 Results 
Whether purified immunoligands retained their binding specificities for all target moieties was the next 
question for assessment. In addition, ULBP2-aCD19-aCD33 was developed as a dual-targeting triplebody 
with specificities for two distinct antigens on cancer cells. It was developed with a rational to target 
antigen loss variants of tumor. Can ULBP2-aCD19-aCD33 still bind to target cells when either CD19 or 
CD33 is blocked was an equally important question. To this end, CD19 and CD33 double positive cell line 
BV173 was used for FACS based binding assay. Binding of triplebody (U-19-33) and both bispecific 
immunoligands (U-19 and U-33) to CD19+CD33+ BV173 cells could be detected by recombinant NKG2D 
receptor suggesting that simultaneous binding to BV173 cells and NKG2D receptor is possible for all 
three immunoligands (figure 20(A)). As BV173 cells express several-fold less molecules of CD33 than 
CD19, the signal intensity for ULBP2-aCD33 binding was low compared to the other two immunoligands.  
As shown in figure 20(A), pre-blocking of CD19 or CD33 antigen prevented ULBP2-aCD19 and ULBP2-
aCD33 to bind, respectively. Blocking of either CD19 or CD33 by respective blocking construct could 
mimic CD19 or CD33 antigen loss variants of BV173 cells: CD19+CD33block or CD19blockCD33+ BV173 cells. 
NKG2D mediated detection revealed that ULBP2-aCD19-aCD33 could retain its specificity for these 
variants even when one of the antigen was blocked. Only simultaneous blocking of CD19 and CD33 
antigens on BV173 cells could completely abolish the binding of ULBP2-aCD19-aCD33 (figure 20(B)). 
Individual specificities of a triplebody ULBP2-aCD19-aCD33 was also checked on CD19+ MEC1 cells. For 
comparison both bispecific immunoligands were also used. Immunoligands were incubated with MEC1 
cells and their CD19-specific binding was detected using recombinant CD33 (with FLAG tag) and NKG2D 
(with Fc tag) receptors. AF647-labeled anti-Fc and PE-labeled anti-FLAG antibodies could detect the 
bound receptors. As shown in figure 21 (“U-19-33”), dual signal in FITC and AF647 channel confirmed 
that ULBP2-aCD19-aCD33 could simultaneously bind to CD19, CD33 and NKG2D through individual 
specificity. Similarly, CD19 antigen bound ULBP2-CD19 could bind to NKG2D receptor as it lacked CD33 
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specific scFv (“U-19”). ULBP2-aCD33 served as a negative control and could not bind to CD19+ but CD33- 
MEC1 cells (“U-33”). 
 
 
 
Figure 21. Simultaneous and antigen specific binding of a triplebody ULBP2-aCD19-aCD33. CD19+ 
MEC1 cell line was incubated with ULBP2-aCD19-aCD33 (U-19-33), ULBP2-aCD19 (U-19) or ULBP2-
aCD33 (U-33) binding was detected using recombinant human NKG2D-Fc and CD33-FLAG receptors 
followed by AF647-labeled anti-Fc and PE-labeled anti-FLAG antibodies, respectively. NKG2D-Fc and 
CD33-FLAG background binding was minimal (No IL – lower left). Data shown in figure was previously 
published in Vyas et al., 2016.   
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5.8. ULBP2-aCD19-aCD33 enhances NK cell dependent killing of CD19/CD33 double 
positive cell lines as well as antigen loss variants 
To investigate the role of a dual-targeting triplebody in NK cell dependent killing of CD19 and CD33 
double positive cells, two B cell precursor leukemia cell lines BV173 and SEM were utilized. NK cells were 
purified from healthy donors and were primed with IL2 (200 U/ml) and IL15 (10 ng/ml). NK cells were 
also routinely characterized for NKG2D expression, activation status and purity and only preparations ≥ 
98% purity were used for experiments.  
ULBP2-aCD19-aCD33 and both bispecific immunoligands enhanced NK cell dependent killing of BV173 
and SEM cell lines (figure 22(A)). Triplebody induced increase in the killing of both cell lines was at least 
2-fold at all E:T ratios and as with ULBP2-aCD19-aCD19, was also more potent than both bispecific 
counterparts in NK cell retargeting. The difference in killing by ULBP2-aCD19 and ULBP2-aCD33 seems to 
be dependent on antigen density on the surface of target cells. ULBP2-aCD33 induced killing was less 
compared to ULBP2-aCD19 for both BV173 and SEM cell lines as the expression of CD33 is several folds 
less than CD19 on the surface of both cell lines. Pre-blocking of NKG2D receptor on NK cells by anti-
NKG2D antibody (clone 1D11) completely abolished the triplebody induced toxicity against both cell 
lines (figure 22(B)). The results of these toxicity assays were supported by independent FACS based 
degranulation assay in response to SEM cells. As shown in figure 22(C), ULBP2-aCD19-aCD33 induced 
around 1.5-fold more NK cells to degranulate in response to SEM. 
In addition, the ability of immunoligands to induce IFNγ production by IL2 and IL15 primed NK cells was 
assessed. NK cells were cultured for 48 hours in the plate pre-coated by immunoligands and SN was 
used to quantify IFNγ by ELISA. Both, bispecific immunoligands and triplebody could augment the 
secretion of IFNγ by NK cells. This was strictly dependent upon the NKG2D and ULBP2 interaction as 
blocking constructs lacking ULBP2 could not induce IFNγ secretion (figure 22(C)). 
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Figure 22. Enhancement of NK cell dependent killing of BV173 and SEM cells by a dual-targeting 
triplebody ULBP2-aCD19-aCD33. (Figure legend on next page)  
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It was revealed that ULBP2-aCD19-aCD33 could retain binding ability to CD19+CD33+ BV173 cells even 
when one of the antigens was blocked. Whether this retained specificity could retarget NK cells against 
antigen loss variants was also checked by FACS based toxicity assay. Similar to binding assay, CD19 or 
CD33 antigen was blocked on BV173 cells to generate single antigen loss variants of otherwise 
CD19+CD33+ BV173 cells: CD19blockCD33+ BV173 and CD19+CD33block BV173. CD19blockCD33block BV173 
represented a variant which lost both antigens from the surface. Toxicity assays with these target cells 
were repeated with IL2 and IL15 primed NK cells from 4 individual healthy donors and one 
representative analysis is shown in figure 23 and a cumulative analysis at 2.5:1 E:T ratio is shown in 
figure 24.  
When both antigens were accessible on BV173 (CD19+CD33+), all three immunoligands (100 nM) 
significantly enhanced the NK-cell dependent killing of BV173 cells in the same trend as previous toxicity 
assays. When CD19 antigen was blocked (CD19blockCD33+) by pre-incubation with molar excess of 
aCD19scFv construct, BV173 killing induced by ULBP2-aCD19 was completely abolished while ULBP2-
Figure 22. Enhancement of NK cell dependent killing of BV173 and SEM cells by a dual-targeting 
triplebody ULBP2-aCD19-aCD33. (A) Target cells (BV173 or SEM) were labeled with DiR and were 
incubated with IL2 + IL15 primed NK cells either alone or in presence of 100 nM immunoligands at 
0.612:1, 1.25:1 and 2.5:1 E:T ratios. (B) NK cells were incubated with 10 µg/ml of mouse anti-human 
NKG2D receptor antibody (clone 1D11) for 30 min on ice to block NKG2D. Excess antibody was 
washed away after 30 min and toxicity assay was set up as described above. For (A) and (B), error 
bars indicate standard error of the mean (SEM) and statistical analysis by One-way ANOVA; N=5 
(BV173) and N=3 (SEM). Each N represents an independent healthy NK cell donor and *P < 0.05; **P 
< 0.01. (C) For FACS based degranulation assay (left), IL2 + IL15 primed NK cells were co-incubated 
with SEM cells in 2.5:1 (E:T) ratio alone or in presence of 100 nM ULBP2-aCD19-aCD33 for 6 hours 
and CD107a stained cells within CD56+ NK cells indicated degranulated NK cells by flow cytometry. 
Error bars indicate standard error of the mean (SEM) and statistical analysis by Paired t-test; N=5. 
Each N represents an independent healthy NK cell donor. For ELISA based IFNγ assay (right), IL2 + 
IL15 primed NK cells were cultured in presence of coated indicated immunoligands (10 µg/ml) for 48 
hours and SN was collected to quantify IFNγ by ELISA. Error bars indicate standard error of the mean 
(SEM) of duplicates. Experiments were conducted with three independent NK donors and one 
example is shown here. Data shown in figure was previously published in Vyas et al., 2016. 
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aCD33 and ULBP2-aCD19-aCD33 retained their toxic effects. Similarly, CD33 blocking on BV173 
(CD19+CD33block) by molar excess of aCD33scFv could abolish killing by ULBP2-aCD33 but not by ULBP2-
aCD19 and the triplebody. Only, complete blocking of both CD19 and CD33 could abolish the killing 
induced by the dual-targeting triplebody. 
 
Figure 23. A dual targeting triplebody ULBP2-aCD19-aCD33 mediates NK cell dependent killing of antigen 
loss variants. IL2 + IL15 primed NK cells were incubated with DiR-labeled BV173 cells at indicated E:T ratio for 
3 hours. After incubation, 7-AAD was added and 7-AAD positive cells within DiR-positive gate indicated dead 
target cells. (BV173 - CD19+CD33+):  As shown in the upper left quadrant, when both antigens were accessible 
on BV173. (BV173 - CD19blockCD33+): As shown in the upper right quadrant, when CD19 antigen was blocked by 
pre-incubation with molar excess of aCD19scFv construct. (BV173 - CD19+CD33block): Similarly, CD33 blocking 
by molar excess of aCD33scFv (lower left quadrant).  (BV173 - CD19blockCD33block): As shown in lower left 
quadrant, simultaneous blocking of both, CD19 and CD33 antigens by respective blocking constructs. One 
representative of 4 independent experiments is shown here (cumulative analysis of N=4 is shown in figure 24).   
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5.9. Resting NK cells can be activated by CD16 stimulation which can be further 
enhanced by NKG2D co-stimulation 
Similar to initial experiments assessing NKG2D stimulation, here CD16a stimulation on NK cells was 
analyzed using Drosophila Schneider-2 cells as “target cell system”. The typical ligand for human CD16a 
(FcγRIIIa) receptor includes Fc part of a human IgG1 antibody, which upon binding to CD16a receptor 
induces antibody dependent cell-mediated cytotoxicity (ADCC). In addition, the Fc part of rabbit IgG 
antibody can also bind and activate CD16a receptor on human NK cells. Here, rabbit polyserum raised 
Figure 24. A dual targeting triplebody ULBP2-aCD19-aCD33 mediates NK cell dependent killing of 
antigen loss variants (cumulative analysis; N=4). This figure is a cumulative analysis of a toxicity 
assay at 2.5:1 (E:T) ratio shown in figure 23 (please refer to the figure legend for detailed 
explanation). Error bars indicate standard error of the mean (SEM) and statistical analysis by One-
way ANOVA; N=4. Each N represents an independent healthy NK cell donor.  
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against Schneider-2 cells was used for stimulation of CD16a receptor. Schneider-2 cells were incubated 
with 1:10,000 dilution of rabbit polyserum for 30 min at room temperature. These rabbit antibody 
coated Schneider-2 cells were used as target cells against IL2 (10 U/ml) cultivated resting human NK cells 
to assess activation via CD69 and degranulation via CD107a markers by flow cytometry. The detailed 
protocol is explained in section 1 (S2 + ULBP1 – NKG2D assays) and gating strategies are in figure 2.  
 
Figure 25. Activation and degranulation of resting NK cells by CD16 stimulation can be further 
enhanced by co-stimulation of NKG2D receptor on IL2 + IL15 primed NK cells. (A) Resting NK cells 
(10 U/ml IL2) were incubated with drosophila Schneider-2 cells coated with 1:10,000 dilution of anti-
S2 polyserum (S2 + Fc) at 1:1 E:T ratio for 6 hours. NK cell activation (left graph) and degranulation 
(right graph) was assessed by flow cytometry by staining for CD69 or CD107a, respectively. Wild type 
un-coated Schneider-2 cells (S2) were used as control in both experiments. Error bars indicate 
standard error of the mean (SEM) and statistical analysis by Student’s t-test; N=3. (B) Schneider-2 
cells transfected with ULBP1 (S2-ULBP1+) and WT (S2) were coated with 10-fold dilutions of anti-S2 
polyserum (Fc) and were co-incubated with IL2 + IL15 primed NK cells for 6 hours and NK cell 
degranulation was assessed as described above. Error bars indicate standard error of the mean 
(SEM) and statistical analysis by Student’s t-test; N=4.       
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As shown in figure 25(A), only CD16a stimulation by coated Schneider-2 cells activates and degranulates 
a significantly, several-fold higher proportion of resting NK cells compared to incubation with uncoated 
WT Schneider-2 cells. Previously, I could show that NK cell degranulation through NKG2D receptor by 
ULBP1 on Schneider-2 cells required IL2 and IL15 priming. Therefore, co-stimulation of NKG2D and 
CD16a receptors on IL2 + IL15 primed NK cells were studies in terms of NK cell degranulation. To this 
end, Schneider-2 cells, either transfected with ULBP1 or WT (untransfected), were incubated with 10-
fold dilutions of rabbit polyserum starting at 1:10,000 dilution and were used as target cells against IL2 + 
IL15 primed NK cells in FACS based degranulation assay. At anti S2-serum dilution 1:10,000 or 1:104, 
CD16a stimulation was more dominating and only a little enhancement of NKG2D stimulation could be 
observed. The additive effect of NKG2D stimulation became more pronounced with increasing anti-S2 
serum dilutions. 1:106 dilution of serum showed the best additive effects of combined NKG2D and 
CD16a stimulation on NK cells (figure 25(B)). 
5.10. A dual-activating triplebody ULBP2-aCD19-aNKR can retarget resting and freshly 
isolated NK cells against target cells 
Cloning of a dual-activating triplebody pL(ULBP2-aCD19-aNKR) was done in similar way as previous both 
triplebodies and was confirmed by restriction digestions and sequencing. Although, ULBP2-aCD19-aNKR 
utilized the same secretion leader sequence (ULBP2) and was comparable in size to previous 
triplebodies, it was not readily secreted from HEK293T cells. Chinese hamster ovary (CHO) cells were 
slightly better in facilitating its secretion and therefore, the expression vector pL(ULBP2-aCD19-aNKR) 
was transfected into Chinese hamster ovary (CHO) cells and stable clones were selected with Zeocin™ as 
the plasmids also expressed Zeocin-resistance gene. Stable clones (polyclonal) were subsequently 
cultured in serum free CD293 medium and SN was collected every 2-3 days over a period of 2-3 weeks. 
His-tag based purification of ULBP2-aCD19-aNKR was not successful due to the low yield of triplebody in 
the SN of transfected CHO cells. Therefore, collected SN was filtered to remove proteins or other 
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contaminants smaller than 90 kDa and was concentrated around 10-fold to increase the concentration 
of triplebody. This concentrated SN was separated on SDS-PAGE and was stained with c-Myc tag specific 
antibody to find that the triplebody was of the expected molecular size (figure 26(B)). Importantly, 
simultaneous binding of ULBP2-aCD19-aNKR to CD19 and recombinant NKG2D or NKR receptor was 
detected by FACS. ULBP2-aCD19-aNKR in the form of 10 µl concentrated SN bound to CD19 on BV173 
cells as well as to recombinant human NKG2D or NKR receptors. As with previous immunoligands, 
binding of this triplebody was antigen specific as pre-blocking of CD19 by aCD19scFv blocked both 
NKG2D and NKR detections (figure 26(C)). 
 
 
Figure 26. Schematic representation, expression and binding specificity of a dual-activating 
triplebody ULBP2-aCD19-aNKR. (A) Cartoon illustrating a dual-activating triplebody ULBP2-aCD19-
aNKR (U-19-aNKR) (B) Triplebody was expressed in eukaryotic cell line CHO and SN was separated 
on SDS-PAGE for protein gel blot staining using anti c-Myc tag antibody. (C) CD19+ BV173 cells were 
incubated with 10 µl of concentrated SN from U-19-aNKR transfected CHO cells. Bound ULBP2-
aCD19-aNKR was detected by recombinant human NKG2D (left) and NKR (right) receptors. Pre-
blocking of CD19 antigen on BV173 cells by 20 µg/ml of aCD19scFv blocked the binding of the 
triplebody.  
aNKR 
U-19-aNKR U-19-aNKR 
NKR receptor 
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Next, I addressed whether the addition of an anti-NKR specific scFv to the immunoligand makes it 
potent to activate NK cells. Moreover, activation of NK cells should only be restricted to immunoligands 
that are mobilized on target cells as NK cells activation in the absence of target cells can lead to severe 
side effects in patients. ULBP2-aCD19-aNKR could activate NK cells significantly only in response to 
BV173 cells, while soluble triplebody was not capable in this regard. A dual-targeting triplebody ULBP2-
aCD19-aCD33 had no effect on NK cell activation in response to BV173 cells suggesting that the 
activating signals were provided by aNKRscFv to NKR receptor on NK cells (figure 27). 
 
Toxicity assays with MEC1 and BV173 cell lines utilized resting (IL2 - 10 U/ml) NK cells as effector cells 
and for comparison, respective mono- and dual-targeting triplebodies were used. Presence of ULBP2-
aCD19-aNKR (as 10 µl concentrated SN) significantly enhanced NK cell dependent killing of MEC1 cells as 
at all E:T ratios (figure 28(A)). As control, 10 µl of similarly concentrated SN from untransfected CHO 
Figure 27. ULBP2-aCD19-aNKR activates freshly isolated NK cells only when bound to target cells. 
(A) Freshly purified NK cells from healthy donors were incubated with CD19+ BV173 cells alone or in 
presence of 100 nM ULBP2-aCD19-aCD33 or 10 µl ULBP2-aCD19-aNKR SN for 6 hours. NK cells 
positive for upregulation of CD69 (stained by FITC-labeled anti-CD69) indicated activated NK cells. 
Error bars indicate standard error of the mean (SEM) and statistical analysis by One-way ANOVA; 
N=3. Each N represents an independent healthy NK cell donor. (B) In absence of BV173 cells, soluble 
ULBP2-aCD19-aNKR fails to activate NK cells after 6 hours of incubation. Error bars indicate standard 
error of the mean (SEM) of two independent NK cell donors (N=2). 
ULBP2-aCD19-aNKR 
U-19-aNKR 
ULBP2-aCD19-aNKR 
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cells was added. For one NK cell donor, 10 nM of ULBP2-aCD19-aCD19 was also added for comparison. 
As shown in figure 28(B), NKG2D stimulation alone on resting NK cells could not induce killing of MEC1 
cells. Similarly, ULBP2-aCD19-aNKR  could induce retargeted killing of BV173 cells at both E:T ratios by 
purified NK cells from two independent donors (figure 28(C)).  
 
Figure 28. Dual-activating triplebody ULBP2-aCD19-aNKR enhanced killing of target cells by resting 
NK cells. Purified NK cells were either incubated with 10 U/ml IL-2 (resting; (A, B, C)) or used as 
freshly isolated (D) in FACS based toxicity assays. DiR-labeled target cells were incubated with NK 
cells with 10 nM of ULBP2-aCD19-aCD19 or 10 µl of ULBP2-aCD19-aNKR SN. (A) ULBP2-aCD19-aNKR 
enhanced resting NK cell mediated MEC1 toxicity (N=3). Error bars indicate standard error of the 
mean (SEM) and statistical analysis by Paired t-test. (B) For 1 donor, NKG2D stimulation alone by 
ULBP2-aCD19-aCD19 could not enhance this killing. (C) ULBP2-aCD19-aNKR specific killing of BV173 
cells, represented as x-fold killing. Error bars indicate standard error of the mean (SEM) of two 
experiments by independent healthy NK cell donors (N=2). (D) Purified CLL cells from Binet A stage 
CLL patients as target cells against freshly isolated NK cells from unrelated healthy donor.  
ULBP2-aCD19-aNKR ULBP2-aCD19-aNKR 
ULBP2-aCD19-aNKR 
ULBP2-aCD19-aNKR 
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To test this dual-activating immunoligand on primary CLL cells, freshly isolated NK cells from unrelated 
healthy donors were used as effector cells against isolated malignant B cells from a Binet A CLL patient. 
Neither, freshly isolated NK cells alone or in combination with 10 nM of ULBP2-aCD19-aCD19 could 
induce any killing of primary CLL cells. On the other hand, ULBP2-aCD19-aNKR activated freshly isolated 
NK cells to kill CLL cells in E:T ratio dependent manner (figure 28(D)). 
 
Figure 29. ULBP2-aCD19-aNKR induces secretion of IFNγ and TNFα from NK cells only in response to MEC1 
cells. NK cells were co-incubated with MEC1 cells at 1:1 ratio for 6 hours. ULBP2-aCD19-aNKR in the form of 10 
µl concentrated SN was added. NK cells were fixed and permeabilized to stain intracellularly for IFNγ and 
TNFα. Error bars indicate standard error of the mean (SEM) and statistical analysis by Student’s t-test; N=3.  
ULBP2-aCD19-aNKR ULBP2-aCD19-aNKR 
ULBP2-aCD19-aNKR ULBP2-aCD19-aNKR 
ULBP2-aCD19-aNKR ULBP2-aCD19-aNKR 
Soluble U-19-aNKR Soluble U-19-aNKR 
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The findings of potent and target cell specific NK cell activation and degranulation by ULBP2-aCD19-
aNKR encouraged me to investigate its role in IFNγ and TNFα secretion by NK cells. FACS based cytokine 
assay was as described before (figure 2; C & D) and involved resting and IL2 + IL15 primed NK cells. NK 
cells were incubated with CD19+ cell lines such as MEC1 (figure 29) and BV173 (data not shown) and 10 
µl of ULBP2-aCD19-aNKR SN was added. As shown in figure 29(A), presence of ULBP2-aCD19-aNKR 
significantly enhanced IFNγ and TNFα secreting (resting) NK cell population in response to MEC1 cells 
and this effect by the triplebody was further pronounced for IL2 + IL15 primed NK cells. Importantly, 
triplebody required binding to target cells in order mediate this effect as soluble triplebody in the 
absence of MEC1 cells did not induce the secretion of IFNγ and TNFα (figure 29(C)). 
 
Note: Several of the figures in this section have been published in Vyas et al (2016). This is currently in 
publishing process and is only available as online version.  
 
Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor 
activity in vitro and in vivo against chronic lymphocytic leukemia. 
Vyas M, Schneider A, Shatnyeva O, Reiners K, Tawadros S, Kloess S, Koehl S, Hallek M, Hansen H, von Strandmann 
EP 
Oncoimmunology. 2016 July (Online Publication: http://dx.doi.org/10.1080/2162402X.2016.1211220)  
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6. Discussion 
The crucial role of the activating receptor NKG2D in tumor surveillance by NK cells is supported by the 
fact that tumor cells including CLL acquire various mechanisms to counteract NKG2D mediated NK cell 
recognition and activation [40]. This thesis primarily focuses on NKG2D function and restoration of the 
defective NK cell surveillance of the CLL cells through different formats of NKG2D triggering triplebodies.  
6.1. IL15 priming, either alone or in combination with IL2, is required for NKG2D-
dependent NK cell effector functions 
In this thesis, Schneider-2 cells were transfected to express ULBP1 on the cell surface in order to study 
the cooperation between various cytokines (IL2, IL12, IL15 and IL18) and NKG2D stimulation. The 
Drosophila cell line Schneider-2 has been used previously to study an individual receptor-ligand 
interaction in T and NK cells [75, 79]. ULBP1 is a glycoprotein and serves as an activating ligand for 
NKG2D receptor [40]. Despite having less complex N-linked glycosylation machinery compared to 
mammals, Schneider-2 cells could express functional ULBP1 that localized on the cell surface (figure 1). 
Of note, the O-linked glycosylation in Schneider-2 cells is similar to mammalian cells [80]. NKG2D 
stimulation on resting NK cells by ULBP1 on Schneider-2 cells could not suffice for their activation and 
degranulation (figure 3). This finding is particularly contradicting to the studies that utilized antibodies 
for NKG2D stimulation. Indeed, IL2-primed NK cells could kill FcR+ murine mastocytoma cell line P815 
following NKG2D stimulation by the anti-NKG2D antibody coated on the target cells [76, 81-84]. 
However, the antibody mediated receptor stimulation cannot mimic the physiological interaction 
between a natural ligand and a receptor. Additionally, P815 cells also express ligands that can stimulate 
human NK cell receptors (LFA1 and NKp46), which may have contributed to the redirected lysis of P815 
[83, 84]. Since Schneider-2 cells are derived from an evolutionary distant non-mammalian species, it is 
unlikely that some of the innately expressed molecules on Schneider-2 cells can interact with any 
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receptors on human immune cells [74, 79]. This assumption was tested in this thesis to confirm the 
previous finding that the wild type Schneider-2 cells could not enhance the basal level NK cell activation 
or other effector functions [76, 78]. 
While short (16-18 hours) priming of NK cells by IL12, IL15 or IL18, either alone or in pair-wise 
combinations, enabled NK cell degranulation in response to ULBP1 on Schneider-2 cells (figure 4), the 
regulation of IFNγ and TNFα production by NKG2D stimulation seemed to be more stringent as only NK 
cells primed by IL15 were potent in this regard (figure 5 & 6). For all three experiments, responses of 
IL15 and IL2 + IL15 primed NK cells were comparable, while the resting NK cells (IL2 alone) were not 
responsive to the ULBP1-transfected Schneider-2 cells. The difference in the individual priming ability of 
IL2 and IL15 to augment NKG2D stimulation was striking since both, IL2 and IL15 share two common 
receptor chains (IL2Rβ and IL2Rγ) as well as downstream signaling pathways including Janus kinase [85]. 
Thus, increasing the concentration of IL2 (possibly 1000 U/ml or more) may lead to comparable priming 
by IL15. However, the more probable reason seems to be the distinct temporal expression of their 
respective high affinity receptor α chains. The IL15Rα chain expression reaches its peak after 18-20 
hours after the stimulus (similar to the priming exposure in this thesis), while IL2Rα expression takes 
around 50 hours to reach the maximum level [86]. 
The synergistic cooperation between IL15 priming and NKG2D stimulation in this thesis can be related to 
the upregulation of NKG2D receptor in response to IL15 as observed for these experiments (data not 
shown). This has been a consistent finding by our lab and others in the NK cell field [62, 87]. IL15 has 
shown to induce the transcription of NKG2D, DAP10 and cytotoxic molecules such as perforin [87, 88]. 
Recently, a transcription independent role of IL15 in NKG2D mediated signaling is revealed. Upon IL15 
priming, Janus Kinase 3 (Jak3), a kinase downstream of IL15R, could directly phosphorylate DAP10. This 
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IL15-Jak3 mediated tyrosine phosphorylation of DAP10 (an adaptor molecule of NKG2D receptor) can 
prime the NKG2D-DAP10 complex for NKG2D stimulation [89].  
Taken together, IL15 priming is necessary to induce NKG2D dependent NK cell effector functions such as 
degranulation and the production of IFNγ and TNFα. This synergistic cooperation seems to be an IL15 
mediated transcription dependent and/or independent regulation. Use of Jak3 inhibitors in above 
discussed experiments (figure 3-5) can help to further explore this synergy.  
6.2. Triplebodies show better NK-cell-dependent killing of CLL and MLL target cells 
compared to bispecific counterparts 
To take advantage of NKG2D-depedent effector response, this thesis focused on developing mono- and 
dual-targeting triplebodies (ULBP2-aCD19-aCD19 and ULBP2-aCD19-aCD33, respectively) to retarget NK 
cells against cancer. While the Drosophila system utilized ULBP1 as a ligand for NKG2D, the triplebodies 
contained a different NKG2D ligand ULBP2. The two NKG2D ligands, ULBP1 and ULBP2 share 55-60% 
similarity within the amino acid sequence and are distantly related to other NKG2D ligands MICA/B (20-
25% similarity) [90, 91]. There are considerable differences between the amino acid sequences of all 8 
NKG2D ligands (ULBP1-6, MICA/B) which undoubtedly results in their structural differences (reviewed in 
[92]). Despite some minor differences in their ability to bind to NKG2D receptor, their general functions 
in the context of NK cell activation seem to be redundant up to some extent. This redundancy is 
indicated by a small Japanese population that carries MICA/MICB null haplotype, but still retains healthy 
NK cell immunity. This is most likely due to the other NKG2D ligands that can compensate for the loss of 
MICA/B [93]. In the context of immunoligands this is shown by Kellner et al. who compared two 
immunoligands MICA-7D8 and ULBP2-7D8 each consisting of a distinct NKG2D ligand (MICA or ULBP2) 
genetically fused with the anti-human CD20 scFv from mAb 7D8 [65]. Both, MICA-7D8 and ULBP2-7D8 
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triggered cytotoxicity against CD20+ malignant cells where ULBP2-7D8 was more potent than MICA-7D8 
with respect to the maximum lysis achieved [65].  
Our group has previously developed ULBP2 containing bispecific immunoligands against multiple 
myeloma (ULBP2-BB4), prostate cancer (ULBP2-aPSMA) and colon cancer (ULBP2-CEA) [62-64]. 
Consistent with the previous immunoligands, ULBP2-aCD19-aCD19, ULBP2-aCD19-aCD33 and their 
bispecific counterparts in this study could also enhance NKG2D-dependent NK cell IFNγ secretion and 
degranulation resulting in the target cell killing in antigen specific manner (figure 11 & 22). However, 
priming of NK cells with IL15 was essential, as effector functions of resting NK cells could not be 
triggered by immunoligands (data not shown). Additionally, for both mono-targeting and dual-targeting 
triplebodies, the study confirmed the superior cytotoxic potential of triplebody format over their 
respective bispecific counterparts and this finding was consistent for all tested cell lines as well as 
primary CLL patient cells. These results once again strengthened this consistent finding by Georg Fey and 
colleagues who developed several CD16 receptor specific trispecific immunoconstructs against typical 
leukemia antigens. Trispecific constructs such as aCD33-aCD16-aCD123 could induce killing of target 
cells (CD33+CD123+) at much lower concentration compared to their bispecific counterparts [55, 59].      
This might be due to higher avidity of these triplebodies for their respective target cells, which can 
account for more stable and prolonged target cell coating and subsequent stronger synapse formation 
between NK and target cells. The firm synapse between NK and target cells can allow the interaction 
between other activating receptors on NK cells with their cognate ligands on the target cells, adding to 
the overall activation of NK cells [94]. Interestingly, we have also observed more potent NK cell 
mediated killing of CD19+ CLL cells by a dual-targeting triplebody (ULBP2-aCD19-aCD33) compared to the 
bispecific ULBP2-aCD19 even though the CLL cells were negative for CD33 antigen (data not shown). This 
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suggests that there must be other factors associated with the format of the triplebody (such as higher 
affinity of ULBP2 for NKG2D) that may play a role in heightened NK cell mediated killing.     
6.3. ULBP2-aCD19-aCD19 retargets NK cells against primary CLL cells in both, 
allogeneic and autologous settings 
An allogeneic setting takes advantage of incompatibility between KIRs on donor NK cells and MHC class I 
on target cells. Both, ULBP2-aCD19-aCD19 and ULBP2-aCD19 could induce (IL15 primed) healthy donor-
derived NK cells to kill primary CLL cells. Here again, consistent with the finding on cell lines, triplebody 
was more potent than ULBP2-aCD19 (figure 12). For few CLL patients, the overall killing capacity by NK 
cells was lower than for other CLL samples and MEC1 cell line suggesting some sort of active inhibition 
of healthy NK cells by malignant B cells. However, this was not correlated to the Binet staging and 
ULBP2-aCD19-aCD19 could enhance NK cell dependent killing even for these patients. Much of the NK 
cell inhibition observed in this study could be attributed to the soluble factors present in the serum from 
CLL patients (figure 13). The strong reduction in NK cell dependent killing of MEC1 cells (figure 13) was 
at least in part due to the presence of high levels of soluble MICA/B and ULBP2 (NKG2D ligands) and 
soluble BAG6 (NKp30 ligand) [43]. Presence of soluble NKG2D ligands have been found in most CLL 
patients and soluble ULBP2 was considered a prognostic marker for therapy-free survival in CLL patients 
[45, 95]. Although, only two serum samples were analyzed in this study, there was a trend of stronger 
NK cell inhibition with increasing Binet stage. Irrespective of the disease progression, ULBP2-aCD19-
aCD19 was able to exert its cytotoxic effect even in the presence of high levels of NK cell inhibitory 
factors.  
KIR-dependent inhibition in autologous setting can add to the already defective NK cell activity in CLL 
patients. The ability of ULBP2-aCD19-aCD19 to retarget patients’ own NK cells against the malignant B 
cells is important from the clinical application point of view. Of two CLL patients (both Binet A), ULBP2-
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aCD19-aCD19 was only effective for the patient with higher NK cell number relative to the CLL cell 
subset (NK:CLL – 0.05:1), while the second patient with much lower NK to CLL cell ratio (0.009:1) was 
resistant to the triplebody effect (figure 15). Interestingly, when this innate NK:CLL cell ratio was 
increased by purified NK cells from these patients, the triplebody could retarget autologous NK cells 
against CLL cells for both patients (figure 16).  
This indicates that a smaller NK cell population, outnumbered in relation to the malignant B cells in CLL 
patients, poses an additional limitation to the functional defects in NK and CLL cells. Indeed, in CLL 
patients, a high burden of malignant B cells in peripheral blood naturally reduces NK cell proportion and 
negatively affects the natural and antibody-dependent cytotoxicity of the latter [47]. Median NK to B cell 
ratio in 166 CLL patients (NK:CLL) was found to be 0.07:1 which is much lower compared to the healthy 
people. Moreover, NK:CLL ratio in this study was associated with CLL progression and indication to start 
of the treatment in newly diagnosed patients [48]. Another report also stated that a lower NK:CLL ratio 
(0.02:1) in CLL patients could hamper an antibody mediated NK cell induced ADCC response [47]. 
Taken together, NK cells in CLL patients are not totally defective but are out-numbered by malignant B 
cells. Further, inhibitory soluble factors along with the surface expression of inhibitory molecules on CLL 
cells are equally accountable for impeded NK cell responses in CLL patients.   
6.4. ULBP2-aCD19-aCD19 shows significant in vivo activity - Implications for its 
clinical utility against CLL  
ULBP2-aCD19-aCD19 could efficiently utilize transplanted human PBMCs to prevent the growth of 
xenografted MEC1 cells in immunodeficient (NSG) mice (figure 17). The triplebody (15 µg) was 
administered to the mice once (at the start of the study), which was enough to limit MEC1 growth 
throughout the study period (52 days) in all treated animals, indicating its high serum stability. Another 
interesting finding was that the tumor limiting activity of the triplebody was not dependent on the prior 
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or external priming of PBMC with IL15. T cell-derived IL2 (long exposure) or IL15 produced by monocytes 
may have primed the NK cells for NKG2D response. Importantly, NKG2D is a shared activating receptor 
on γ/δ T cells and a co-activating receptor on CD8+ T cells. A role of the triplebody in retargeting these T 
cell populations cannot be completely ruled out, as NKG2D dependent anti-tumor effector functions of 
CD8+ T cells and γ/δ T cells have been reported [64, 96, 97]. While these exciting features clearly 
propose ULBP2-aCD19-aCD19 for further preclinical development, there are several CLL specific 
challenges that need to be addressed.  
First of all, due to a high burden of CLL cells and subsequent smaller compartments of CD8+ T and NK 
cells (even smaller for γ/δ T cells) in most patients for whom treatment is recommended, it is unlikely 
that a therapeutic strategy such as ULBP2-aCD19-aCD19 can be very effective as a single agent. 
However, if there are no severe side effects, it can be considered as a therapeutic option in very early 
stage CLL patients, who are generally classified for the “wait and watch” group. Alternatively, a strategy 
to expand and prime NK cell population in CLL patients can be potentially synergistic with ULBP2-aCD19-
aCD19. Laprevotte et al used recombinant IL15 to efficiently induce NK cell killing of CLL cells and this 
was associated with the activation and proliferation of autologous NK cells [47]. To this end, I confirmed 
that NK and CD8+ T cells in CLL patients express inherent NKG2D receptor which can be slightly increased 
by IL2 alone while IL15 addition led to the significant upregulation on both, NK (figure 14) and CD8 T 
cells (data not shown). Guven et al reported successful ex vivo expansion of NK and NKT cells from CLL 
patients using IL2 (500 U/ml) despite initial low numbers [52]. This is very exciting in view of adoptive 
transfer of autologous or allogeneic NK cell therapy depending upon the source of the effector 
population and the data of the thesis suggest that additional ex vivo coating of NK cells with ULBP2-
aCD19-aCD19 can further overcome the inhibitory soluble factors in CLL patients and can enhance the 
efficacy of this strategy. 
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Most of the current treatment options for CLL include combinations of several approaches. ULBP2-
aCD19-aCD19 may potentiate the FDA approved Rituximab (anti-CD20 Ab) or a promising 
immunomodulatory drug lenalidomide. Co-targeting of CD16 (receptor for rituximab) and NKG2D on NK 
cells was found to be synergistic (discussed later), while lenalidomide has shown to enhance the NK cell 
responses in CLL [98, 99]. While, FDA approved BTK inhibitor ibrutinib antagonizes CD16 receptor 
dependent rituximab action its effect on NKG2D induced responses are not known [100, 101].     
6.5. Dual-targeting and dual-activating triplebodies - Novel formats to improve 
clinical outcome in CLL 
The clinical value of a triplebody can be further improved by modifying its format. Thus, two additional 
formats (dual-targeting and dual-activating) were developed to address CLL specific limitations.  
ULBP2-aCD19-aCD33 
A dual-targeting format of triplebody was generated to target antigen loss variants in cancer. Only a 
dual-targeting triplebody ULBP2-aCD19-aCD33 could efficiently kill both, CD19loss and CD33loss BV173 
(MLL cell line) variants in a proof-of-principle experiment (figure 23 & 24). CD33 specific scFv can be 
replaced by a scFv against a second CLL antigen such as CD20. Such a CLL specific dual-targeting 
triplebody (ULBP2-aCD19-aCD20) would offer an additional advantage for CD19loss or CD20loss CLL 
patients. Two main mechanisms have been reported for CD20 loss from the CLL cells following rituximab 
(anti-CD20 mAb) treatment. While CD20 internalization by malignant B cells plays a minor role, the 
majority of CD20, along with the bound rituximab, is removed by the Fcγ receptor expressing monocytes 
and macrophages in a process called as trogocytosis or shaving. This does not only result in the rapid 
clearance of rituximab following the infusion, but also leads to selection of CD20- CLL cells that are 
resistant to anti-CD20 therapy. Similarly, CD19 internalization is also reported by anti-CD19 antibody 
XmAb5574 in CLL. Interestingly, Jones et al reported the loss of CD19 from the CLL cells during the 
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shaving (trogocytosis) of anti-CD20 rituximab. It was shown that CD19 was also transferred from B cells 
to monocytes in Fc dependent manner.   
ULBP2-aCD19-aNKR 
The second, dual-activating, format focused on further enhancing the NK cell activity against CLL by 
interacting with NKG2D and NKR receptors on NK cells. Most importantly, ULBP2-aCD19-aNKR could 
induce effector functions from freshly isolated or resting NK cells, a task all previous NKG2D targeting 
immunoligands failed to achieve. The main findings included induction of cytokines (IFNγ and TNFα) and 
toxicity against MEC1 and CLL primary cells using unprimed NK cells.  
It is very likely that most of these potent effects were induced by NKR targeting and NKG2D receptor 
had little, if any, role in it. However, using IL15 primed NK cells and Schneider-2 cells as target, I 
confirmed that NKG2D stimulation can have additive effects even in the presence of strong NKR 
stimulation. Based on the convincing in vivo data of ULBP2-aCD19-aCD19, I believe that the dual-
activating triplebody ULBP2-aCD19-aNKR may provide the initial strong NKR stimulation. But the 
triggering of NKG2D on NK as well as CD8+ T cells in the presence of IL2 or IL15 might be just as 
important, since it also involves the adaptive immune response and thus results in a more dynamic 
immune response.  
6.6. Future perspectives 
Further development of a dual-targeting immunoligand to target antigen loss variants in CLL is planned. 
To this end, a triplebody with dual, CD19 and CD20 specificity will be developed while maintaining 
ULBP2 for NKG2D targeting. It will be important to analyze its activity on CLL cells from patients 
presented with antigen loss variants following rituximab therapy as well as in a relevant mouse model. 
An immunodeficient mouse model engrafted with CD19loss B cell ALL blasts from a patient who relapsed 
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after CD19-specific chimeric antigen receptor (CAR) T cell therapy was recently used to study the effect 
of dual-targeting CAR T cells [102]. 
The production of ULBP2-aCD19-aNKR was challenging and the focus would on modifying the system to 
improve its yield. Whether NKG2D and NKR receptors, both, can play a role in mounting an immune 
response will be of prime interest. It is also expected that this construct will be particularly effective in 
mounting a strong NK response and in activating adaptive immunity through NKG2D positive T cells. This 
idea of synergy at the cellular level has not been tested yet and would be very interesting to explore.  
Finally, information on NKp30 receptor in the context of cooperation with other activating (CD16, 2B4, 
NKG2D) or adhesion (LFA1) receptors on NK cells is elusive. B7-H6 is recently identified as a ligand for 
NKp30 [37]. Therefore, Schneider-2 cells expressing B7-H6 alone or in pair-wise combinations with other 
ligands (ULBP1, ICAM1 etc.) have been generated and initial data showed that NKp30 has similar (to 
NKG2D) cytokine requirements.  
6.7. Conclusion 
IL15 priming of NK cells is required to induce NKG2D dependent NK cell effector functions, especially 
cytokine secretion. The synergistic cooperation between IL15 and NKG2D was efficiently exploited by 
the mono-targeting triplebody ULBP2-aCD19-aCD19 in retargeting NK cells against CLL cells. Surprisingly, 
the superior in vivo efficacy of this triplebody in NSG mouse model did not require external IL15 
administration. Dual-targeting and dual-activating triplebody formats further extended the usefulness of 
this NK cell-based strategy to tackle clinically relevant CLL issues.     
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Abbreviations  
 
7-AAD 7-aminoactinomycin D 
Ac5 Actin 5  
ADCC Antibody Dependent Cell mediated Cytotoxicity  
AF647 Alexa Fluor 647 
Amp Ampere 
ANOVA Analysis of variance 
B7-H6 Member of the B7 family of immunoreceptors 
BAG6 BCL2-associated athanogene 6 
B-ALL B-cell acute lymphocytic leukemia  
BAT3 HLA-B-associated transcript 3 
B-CLL Chronic Lymphocytic Leukemia of B cells 
BFA Brefeldin A 
BiTE Bispecific T-cell engager  
BTK Bruton’s Tyrosine Kinase  
BV421 Brilliant Violet 421 
CAR Chimeric antigen receptor  
CD cluster of differentiation 
CEA Carcinoembryonic antigen 
CHO cells Chinese hamster ovarian cells 
CLL Chronic Lymphocytic Leukemia  
CTLA-4 cytotoxic T-lymphocyte-associated protein 4 
DAP10 DNAX-activation protein 10 
DC Dendritic Cell 
DNA Deoxyribonucleic acid  
DNAM-1 DNAX Accessory Molecule-1 
DTT Dithiothreitol 
E:T Effector to target 
EGFP Enhanced green fluorescent protein 
ELISA Enzyme linked immunosorbent assay 
ER Endoplasmic reticulum  
FACS Fluorescence-activated cell sorting (flow  cytometry) 
Fc Fragment crystallizable 
FcγRIIIa Fc gamma receptor IIIa 
FDA Food and Drug Administration 
FITC Fluorescein isothiocyanate 
GFP Green fluorescent protein 
Gly/Ser Glycine / serine  
Grb2 Growth factor receptor-bound protein 2 
GvHD Graft versus Host Disease 
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GvL Graft versus Leukemia  
HBS Hepes Buffered Saline 
HBSS Hank's Balanced Salt Solution 
HEK293T cells Human embryonic kidney 293T cells 
His Histidine  
HLA Human Leukocyte Antigen 
HRP Horse radish peroxidase  
HSCs Hematopoietic Stem Cells 
HSCT Hematopoietic Stem Cell Transplantation 
ICAM1 Intercellular Adhesion Molecule 1 
IFNγ Interferon gamma 
IgG Immunoglobulin G 
Igk Immunoglobulin kappa  
IL Interleukin  
IL15Rα Interleukin 15 receptor 15 α chain 
IL2Rγ/β Interleukin 15 receptor 15 γ/β chain 
IMAC Immobilized Metal Affinity Chromatography 
ITAM Immunoreceptor tyrosine-based activation motif 
ITIM Immunoreceptor tyrosine-based inhibition motif 
ITSM Immunoreceptor tyrosine-based switch motif 
Jak3 Janus kinase 3 
Kb Kilobase 
kDa Kilo Dalton 
KIRs Killer-cell immunoglobulin-like receptors 
LAMP-1 lysosome-associated membrane glycoprotein 1 
mAb Monoclonal antibody 
MACS Magnetic-activated cell sorting  
MHC-I Major Histocompatibility Class – I 
MICA MHC-I related chain A 
MICB MHC-I related chain B 
MLL Mixed Lineage Leukemia  
MMPs Matrix Metalloproteinases  
MRD Minimal Residual Disease 
NCI National Cancer Institute  
NCRs Natural Cytotoxicity Receptors 
NK Natural Killer 
NKG2D Natural killer group 2, member D 
NKp30 Natural killer cell protein 30 
NKp44 Natural killer cell protein 44 
NKp46 Natural killer cell protein 46 
NSG NOD scid gamma 
PAGE Polyacrylamide agarose gel electrophoresis  
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PB Pacific Blue 
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate buffered saline  
PBST Phosphate buffered saline + Tween 20 
PCNA Proliferating cell nuclear antigen 
PD-1 Programmed cell death protein 1 
PE Phycoerythrin 
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PLCγ1 phospholipase Cγ1 
PSMA Prostate specific membrane antigen 
RT Room temperature  
S/N or SN Supernatant  
S2 cells Schneider-2 cells 
scFv Single-chain variable fragment 
SDS Sodium dodecyl sulfate  
SEM Standard error of the mean 
SyK Spleen tyrosine kinase 
TGFβ Transforming growth factor β 
TNFα Tumor Necrosis Factor alpha 
TRAIL TNF-related apoptosis-inducing ligand 
U Units 
ULBP1 UL16 binding protein 1 
ULBP2 UL16 binding protein 2 
V Voltage 
Vav1 Vav 1 guanine nucleotide exchange factor 
VH Variable heavy chain  
VL Variable light chain  
WT Wildtype 
ZAP70 Zeta-chain-associated protein kinase 70 
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